{
  "meta": {
    "title": "Pharmacology_Test",
    "url": "https://brainandscalpel.vercel.app/pharmacology-test-822057c7.html",
    "scrapedAt": "2025-11-30T12:49:24.200Z"
  },
  "questions": [
    {
      "text": "Co-trimoxazole is a combination of trimethoprim with sulfamethoxazole in the ratio of __________",
      "choices": [
        {
          "id": 1,
          "text": "5:1"
        },
        {
          "id": 2,
          "text": "1:5"
        },
        {
          "id": 3,
          "text": "1:20"
        },
        {
          "id": 4,
          "text": "20:1"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Co-trimoxazole</strong> is a <strong>combination of trimethoprim</strong> with <strong>sulfamethoxazole in the ratio of 1:5</strong>. Sulfamethoxazole is an intermediate-acting sulfonamide with a plasma half-life of around 10 hours.&nbsp;Trimethoprim also has a similar plasma half-life and therefore combined with sulfamethoxazole.</p>\n<p>Due to a difference in pharmacokinetic (absorption in GIT) properties of the two drugs, this cannot be achieved by administering them at a dose having the same ratio. Therefore, it is administered at a <strong>dose ratio of 1:5</strong>&nbsp;(<strong>trimethoprim: sulfamethoxazole</strong>) which leads to a <strong>plasma&nbsp;ratio of 1:20</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2594",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged woman with schizoaffective disorder was recently prescribed a different antipsychotic drug instead of the one she was usually taking. She is also on sertraline. She presented a month later, complaining of breast engorgement, galactorrhea, and amenorrhea. Investigations revealed highly elevated prolactin levels. The drug most likely prescribed was?",
      "choices": [
        {
          "id": 1,
          "text": "Brexpiprazole"
        },
        {
          "id": 2,
          "text": "Risperidone"
        },
        {
          "id": 3,
          "text": "Clozapine"
        },
        {
          "id": 4,
          "text": "Aripiprazole"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The above clinical scenario is suggestive of<strong> hyperprolactinemia</strong> secondary to the use of <strong>risperidone</strong>,&nbsp;an<strong>&nbsp;atypical antipsychotic </strong>that can be used in schizoaffective disorder.</p>\n<p>The clinical symptoms are indicative of <strong>hyperprolactinemia</strong>, most likely caused by the <strong>dopamine antagonist</strong> <strong>action</strong> of risperidone. Normally, prolactin secretion is inhibited by dopamine. Therefore, drugs that act as dopamine antagonists lead to loss of this inhibitory action and cause hyperprolactinemia. This results in symptoms like <strong>breast engorgement, galactorrhea, amenorrhea</strong> in women, and infertility in men.&nbsp;</p>\n<p>Risperidone&nbsp;is an <strong>atypical antipsychotic</strong> indicated in the management of schizophrenia, acute mania or mixed with bipolar disorder, aggressive episodes in autism spectrum disorder, etc. It&nbsp;is an <strong>antagonist</strong> of the <strong>serotonin 5-HT2A</strong>, <strong>dopamine D2</strong>, a1-adrenergic,&nbsp;a2-adrenergic, and<strong> histamine H1 receptors</strong>.</p>\n<p>In&nbsp;<strong><span class=\"s1\">schizoaffective disorder</span></strong><span class=\"s1\">,&nbsp;symptoms of </span><span class=\"s1\"><strong>mania</strong> or <strong>depression</strong> develop concurrently with the major symptoms of<strong> schizophrenia.</strong> Thus, they are treated with mood stabilizers for manic episodes (like carbamazepine) or s</span>elective serotonin reuptake inhibitors (like sertraline) for depressive episodes. Antipsychotics are prescribed for psychotic symptoms.</p>\n<p>In this patient, sertraline was administered along with risperidone. The combined use of <strong>risperidone</strong> and <strong>selective serotonin reuptake inhibitors</strong> (as in this patient) can result in a significant elevation of prolactin levels. This is due to the CYP2D6 enzyme inhibitory actions of SSRIs, thereby inhibiting the metabolism of other CYP2D6 substrates.&nbsp;</p>\n<p>This hyperprolactinemia can be rapidly reversed by discontinuing the drug or switching to other low potency/ prolactin sparing (eg. quetiapine) atypical antipsychotics. In case, risperidone needs to be continued, administering <strong>bromocriptine</strong> can alleviate the symptoms.&nbsp;</p>\n<p>Other options:</p>\n<p><strong>Brexpiprazole, clozapine, and aripiprazole </strong>are atypical antipsychotics. they do not have any effect on prolactin secretion.</p><hr><h3>Related Pearl: Antipsychotic drugs and their potential to cause side effects</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Side effect</strong></span></div>\n</td>\n<td>\n<div><span><strong>Highest potential</strong></span></div>\n</td>\n<td>\n<div><span><strong>Least potential</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Anticholinergic</strong></span></div>\n</td>\n<td>\n<div><span>Chlorpromazine, Thioridazine&nbsp;</span></div>\n</td>\n<td>\n<div><span>Haloperidol, Risperidone</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Hypotension</strong></span></div>\n</td>\n<td>\n<div><span>Chlorpromazine, Clozapine</span></div>\n</td>\n<td>\n<div><span>Haloperidol, Aripiprazole</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Sedation</strong></span></div>\n</td>\n<td>\n<div><span>Clozapine, Chlorpromazine</span></div>\n</td>\n<td>\n<div><span>Aripiprazole, Ziprasidone</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Metabolic syndrome</strong>,&nbsp;<strong>Diabetes</strong></span></div>\n</td>\n<td>\n<div><span>Clozapine, Olanzapine</span></div>\n</td>\n<td>\n<div><span>Aripiprazole, Ziprasidone</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Weight gain</strong></span></div>\n</td>\n<td>\n<div><span>Clozapine, Olanzapine</span></div>\n</td>\n<td>\n<div><span>Aripiprazole, Haloperidol</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Hyperprolactinemia</strong></span></div>\n</td>\n<td>\n<div><span>Amisulpride, Haloperidol, Risperidone</span></div>\n</td>\n<td>\n<div><span>Aripiprazole, Quetiapine</span></div>\n<div><span>Clozapine, Olanzapine- almost zero risk (mild risk)</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Extrapyramidal effects</strong></span></div>\n</td>\n<td>\n<div><span>Haloperidol</span></div>\n</td>\n<td>\n<div><span>Clozapine, Quetiapine</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Non extrapyramidal side effects of antipsychotics</h3><p>&nbsp;</p>\n<p><strong>Typical antipsychotics</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Drug</strong></td>\n<td><strong>Side effects</strong></td>\n</tr>\n<tr>\n<td>Chlorpromazine</td>\n<td>Corneal &amp; lenticular deposits, <strong>vortex keratopathy</strong>, obstructive jaundice</td>\n</tr>\n<tr>\n<td>Thioridazine</td>\n<td>Irreversible <strong>retinal pigmentation</strong>,&nbsp;QT prolongation</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Atypical antipsychotics</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Drug</strong></td>\n<td><strong>Side effects</strong></td>\n</tr>\n<tr>\n<td>Clozapine</td>\n<td><strong>Agranulocytosis,</strong> metabolic syndrome, diabetes, weight gain, <strong>wet pillow syndrome</strong> (excessive night time drooling)</td>\n</tr>\n<tr>\n<td>Olanzapine</td>\n<td>Metabolic syndrome, diabetes, weight gain</td>\n</tr>\n<tr>\n<td>Quetiapine</td>\n<td><strong>Cataract</strong></td>\n</tr>\n<tr>\n<td>Ziprasidone</td>\n<td><strong>QT prolongation</strong></td>\n</tr>\n<tr>\n<td>Amisulpride</td>\n<td>Hyperprolactinemia</td>\n</tr>\n<tr>\n<td>Aripiprazole</td>\n<td><strong>Hypoprolactinemia</strong>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7629",
      "difficulty": "easy"
    },
    {
      "text": "Identify the drug which causes this adverse effect ________",
      "choices": [
        {
          "id": 1,
          "text": "Ergotamine"
        },
        {
          "id": 2,
          "text": "Sumatriptan"
        },
        {
          "id": 3,
          "text": "Butorphanol"
        },
        {
          "id": 4,
          "text": "Aspirin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ergotamine</strong> causes occlusion of peripheral blood vessels in susceptible persons. It acts as a partial agonist and antagonist at&nbsp;&alpha; adrenoreceptors and all subtypes of 5HT<sub>1</sub> and 5HT<sub>2</sub> serotonin receptors.</p>\n<p>The numbness progressing to bluish discoloration of the fingers are the initial signs of occlusion. It can lead to gangrene if left untreated eventually leading to amputation. Nausea and vomiting, as well as tingling and numbness (paresthesia), are common adverse effects of ergotamine.</p>\n<p>Contraindications for ergotamine:&nbsp;</p>\n<ul>\n<li>Peripheral vascular disease</li>\n<li>Coronary artery disease</li>\n<li>Uncontrolled hypertension</li>\n<li>Fever and/or sepsis</li>\n<li>Pregnancy</li>\n<li>Within 24 hours of using triptans</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/154676739a8046639bf523c9c152b4c6.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1856",
      "difficulty": "easy"
    },
    {
      "text": "A 52-year-old female patient with type 2 diabetes mellitus has been prescribed pioglitazone. What will you tell her when she asks about the most common adverse effect of thiazolidinediones?",
      "choices": [
        {
          "id": 1,
          "text": "Compensated heart failure"
        },
        {
          "id": 2,
          "text": "Weight gain and edema"
        },
        {
          "id": 3,
          "text": "Osteoporosis"
        },
        {
          "id": 4,
          "text": "Liver dysfunction"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The most common adverse effects of the thiazolidinediones are&nbsp;</span><strong><span data-preserver-spaces=\"true\">weight gain and edema</span></strong><span data-preserver-spaces=\"true\">.</span></p>\n<p><span data-preserver-spaces=\"true\">Thiazolidinediones are a selective agonist of nuclear&nbsp;</span><strong><span data-preserver-spaces=\"true\">peroxisome proliferator-activated receptor gamma&nbsp;</span></strong><span data-preserver-spaces=\"true\">(PPAR-&gamma;). They modulate the expression of genes involved in lipid and glucose metabolism, insulin signal transduction, and adipocyte differentiation. These effects increase the sensitivity of the tissues to insulin.</span></p>\n<p><span data-preserver-spaces=\"true\">Pioglitazone and rosiglitazone are used to treat patients with type 2 diabetes. They are known to cause f</span>luid retention and edema<span data-preserver-spaces=\"true\">&nbsp;and therefore avoided in patients who have heart failure.&nbsp;</span></p>\n<p><span data-preserver-spaces=\"true\">Pioglitazone is metabolized in the liver and constant liver function monitoring is required as it is hepatotoxic. It is thus contraindicated in liver disease.</span></p><hr><h3>Related Pearl: Factors affecting insulin secretion</h3><table>\n<tbody>\n<tr>\n<td><strong>Stimulators</strong></td>\n<td><strong>Inhibitors</strong></td>\n</tr>\n<tr>\n<td>\n<p>Glucose</p>\n<p>Mannose</p>\n</td>\n<td>\n<p>2-Deoxyglucose</p>\n<p>Mannoheptulose</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glucagon</p>\n</td>\n<td>Somatostatin&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Amino acids - leucine arginine</p>\n<p>Intestinal hormones - GIP, GLP-1, gastrin, secretin, CCK</p>\n</td>\n<td>K<sup>+</sup> depletion&nbsp;</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p>&nbsp;</p>\n<p>Leptin</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Acetylcholine (Parasympathetic stimulation )</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>&beta;-adrenergic stimulators</p>\n<p>Theophylline</p>\n<p>Sulfonylureas</p>\n</td>\n<td>\n<p>&alpha;-adrenergic stimulators (norepinephrine, epinephrine)&beta;-Adrenergic blockers&nbsp; (propranolol)</p>\n<p>Diazoxide</p>\n<p>Thiazide diuretics</p>\n<p>Phenytoin&nbsp;</p>\n<p>Alloxan</p>\n<p>Microtubule inhibitors ( Taxanes, Vinca alkaloids)</p>\n<p>Insulin</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Comparative Features of Type I and Type II Diabetes mellitus</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Type 1 DM</strong></p>\n</td>\n<td>\n<p><strong>Type 2 DM</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Etiology</strong></p>\n</td>\n<td>\n<p>Autoimmune</p>\n</td>\n<td>\n<p>Insulin resistance which later leads to impaired insulin secretion</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Age at onset</strong></p>\n</td>\n<td>\n<p>Usually young children</p>\n</td>\n<td>\n<p>Adult</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>HLA association</strong></p>\n</td>\n<td>\n<p><strong>DR3, DR4</strong></p>\n</td>\n<td>\n<p>No HLA association</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Body weight</strong></p>\n</td>\n<td>\n<p>Normal / Underweight</p>\n</td>\n<td>\n<p><strong>Obese</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Family history</strong></p>\n</td>\n<td>\n<p>May or may not be positive</p>\n</td>\n<td>\n<p>Usually<strong> strongly positive</strong>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Presentation</strong></p>\n</td>\n<td>\n<p>Abrupt</p>\n</td>\n<td>\n<p>Gradual or symptomatic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Insulin requirement</strong></p>\n</td>\n<td>\n<p>Absolute</p>\n</td>\n<td>\n<p>Oral hypoglycemics, later insulin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Serum insulin level / C peptide level</strong></p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>High</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>&nbsp;</strong></p>\n<p><strong>Clinical Features</strong></p>\n</td>\n<td>\n<p><strong>Diabetic ketoacidosis</strong> is common&nbsp;</p>\n<p>It is associated with other autoimmune diseases like:</p>\n<p><strong>Thyroid disorders</strong></p>\n<ul>\n<li>Addison's disease</li>\n<li>Rheumatoid arthritis</li>\n<li>Schmidt syndrome/ Polyglandular failure syndrome</li>\n</ul>\n</td>\n<td>\n<p><strong>Non-ketotic hyperosmolar coma</strong> is common</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4973",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old male patient was diagnosed with pulmonary artery hypertension. He was prescribed an endothelin receptor antagonist for the management of the same. After starting the drug, he developed nasal congestion and pharyngitis. Which of the following drugs was prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Epoprostenol"
        },
        {
          "id": 2,
          "text": "Bosentan"
        },
        {
          "id": 3,
          "text": "Inhaled nitric oxide (NO)"
        },
        {
          "id": 4,
          "text": "Sildenafil"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug prescribed is <strong>bosentan</strong>. </p>\n<p>The clinical scenario of the development of <strong>nasal congestion and pharyngitis</strong> after administration of an <strong>endothelin receptor antagonis</strong>t given for the treatment of pulmonary artery hypertension suggests that the drug prescribed is bosentan.</p>\n<ul>\n<li><strong>ET</strong><sub><strong>A</strong> - </sub>This receptor is localized on the<strong> pulmonary artery smooth muscle cell</strong>. It is a <strong>G-protein coupled receptor </strong>and acts via the <strong>IP<sub>3</sub>-DAG</strong> pathway elevating cytosolic Ca<sup>2+ </sup>thus causing <strong>vasoconstriction</strong>.</li>\n<li><strong>ET<sub>B</sub></strong> - This receptor is present on the pulmonary artery smooth muscle cell and <strong>endothelial cell</strong>. It is a <strong>G-protein coupled receptor </strong>and on activation, the ET<sub>B </sub>receptors on the endothelial cells increase the production of <strong>PGI<sub>2, </sub>NO and inhibit ET-1 production.</strong></li>\n</ul>\n<p>Endothelin receptor antagonists act by either non-selectively inhibiting both endothelin receptors or by selectively inhibiting ET<sub>A </sub>receptors only. The <strong>nonselective </strong>endothelin receptor antagonists are <strong>bosentan </strong>and <strong>macitentan. </strong>The <strong>selective</strong> endothelin receptor antagonists are <strong>ambrisentan </strong>and <strong>sitaxsentan. </strong><strong>Sitaxsentan</strong> is the <strong>most selective</strong> <strong>ET<sub>A</sub></strong> receptor <strong>antagonist.</strong> These drugs are predominantly used in the treatment of pulmonary artery hypertension.</p>\n<p>Side effects:</p>\n<ul>\n<li><strong>Headache</strong></li>\n<li><strong>Pulmonary edema</strong></li>\n<li><strong>Nasal congestion</strong>/<strong>pharyngitis</strong></li>\n<li><strong>Hepatotoxicity - </strong> needs monitoring and <strong>contraindicated </strong>in patients with mild-moderate liver disease.</li>\n<li><strong>Teratogenic</strong> - <strong>contraindicated </strong>in <strong>pregnancy</strong>.</li>\n</ul>\n<p>Other options:</p>\n<p>Option A- <strong>Epoprostenol</strong> is a <strong>synthetic PGI</strong><sub><strong>2</strong>, </sub>It acts by inhibiting myosin light chain kinase and activating K+ channels. It is the mainstay of treatment of pulmonary artery hypertension, particularly in advanced stages. The important side effects include <strong>myalgia, jaw pain, nausea, flushing, and systemic hypotension.</strong></p>\n<p>Option C- <strong>Inhaled NO</strong> acts by <strong>activation</strong> of<strong> soluble guanylyl cyclase</strong> → activates cyclic guanosine monophosphate (cGMP). An important side effect is <strong>methemoglobinemia.</strong></p>\n<p>Option D- <strong>Sildenafil</strong> acts by competitive <strong>inhibition</strong> of <strong>phosphodiesterase</strong> <strong>5</strong> (PDE5). Important side effects are <strong>headache, flushing </strong>and <strong>blue-green vision</strong>.</p><hr><h3>Related Pearl: Drugs used in Pulmonary Arterial Hypertension (PAH)</h3><table>\n<tbody>\n<tr>\n<td><strong>Drug Class</strong></td>\n<td><strong>Examples</strong></td>\n</tr>\n<tr>\n<td>Prostacyclin derivative</td>\n<td>\n<p>Epoprostenol</p>\n<p>Iloprost</p>\n<p>Treprostinil</p>\n</td>\n</tr>\n<tr>\n<td>Endothelin receptor antagonist</td>\n<td>\n<p>Bosentan</p>\n<p>Ambrisentan</p>\n<p>Macitentan</p>\n</td>\n</tr>\n<tr>\n<td>PDE5 inhibitor</td>\n<td>\n<p>Sildenafil</p>\n<p>Tadalafil</p>\n</td>\n</tr>\n<tr>\n<td>Soluble guanyl cyclase stimulator</td>\n<td>Riociguat</td>\n</tr>\n<tr>\n<td>Calcium channel blocker</td>\n<td>\n<p>Nifedipine</p>\n<p>Diltiazem</p>\n<p>Amlodipine</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1739",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old female patient presented with the following finding. Her medical history includes hypertension for which she has been taking regular medications for the past 3 months. Which of the following medication is most likely to be associated with this finding?",
      "choices": [
        {
          "id": 1,
          "text": "Enalapril"
        },
        {
          "id": 2,
          "text": "Telmisartan"
        },
        {
          "id": 3,
          "text": "Amlodipine"
        },
        {
          "id": 4,
          "text": "Hydrochlorthiazide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image shows<strong> pitting pedal edema</strong> in a hypertensive patient. <strong>Calcium channel blockers (CCBs)</strong> like <strong>amlodipine</strong> are most likely to be associated with peripheral edema.</p>\n<p>The frequency of CCB- induced peripheral edema is both <strong>drug-specific</strong> (i.e more potent drugs like amlodipine will be associated with higher rates of developing edema) and <strong>dose-dependent</strong> (i.e incidence of edema increases with an increase in drug dosage and chronicity of its usage). It is more common among <strong>females.</strong></p>\n<p>CCB-induced peripheral edema occurs due to a disproportionate decrease in the&nbsp;arteriolar resistance than in the venous circulation, resulting in increased&nbsp;hydrostatic pressure in the precapillary circulation. This leads to a fluid shift&nbsp;into the interstitial compartment causing edema.</p>\n<p>Treatment:</p>\n<ul>\n<li>Dose reduction.</li>\n<li>Interclass switching of CCB - switch to non-dihydropyridines like verapamil, and diltiazem.</li>\n<li>Addition of a venodilator - ACE inhibitor, ARBs, Nitrates.</li>\n<li>Others - compression stockings, avoiding prolonged upright position.</li>\n<li>Definitive treatment would be discontinuation of the CCB and switching to another class of antihypertensives.</li>\n</ul>\n<p>Other options:</p>\n<p>Option A: Common side effects of <strong>ACE inhibitors</strong> like <strong>enalapril </strong>include hypotension, hyperkalemia, dry cough, rashes, urticaria, dysgeusia, gastrointestinal upset, headache, and dizziness.</p>\n<p>Option B:<strong>&nbsp;Telmisartan</strong>, an angiotensin receptor blocker (<strong>ARBs)</strong>, causes adverse effects such as hypotension, hyperkalemia, headache, gastrointestinal upset, and dizziness.</p>\n<p>Option D: Adverse effects of <strong>thiazide diuretics</strong> like <strong>hydrochlorothiazide</strong> are hypokalemia, hyponatremia, hyperglycemia, hyperuricemia, hypercalcemia, rashes,&nbsp;headache, gastrointestinal upset, and dizziness.</p><hr><h3>Related Pearl: European society of cardiology guidelines for treatment of hypertension</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Indication</strong></p>\n</td>\n<td>\n<p><strong>Initial treatment of choice&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypertension alone or hypertension with diabetes/ cerebrovascular disease</p>\n</td>\n<td>\n<p>ACEi/ARB + CCB/diuretic (A+C or A+D)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypertension with coronary artery disease</p>\n</td>\n<td>\n<p>ACEi/ ARB + beta blocker/CCB (A+B or A+C)</p>\n<p>or</p>\n<p>beta-blocker + diuretic (B+D)</p>\n<p>or&nbsp;</p>\n<p>CCB+ diuretic/ beta-blocker (C+B or C+D)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypertension with chronic kidney disease</p>\n</td>\n<td>\n<p>ACEi/ARB + CCB/diuretic (A+C or A+D)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypertension with heart failure and reduced ejection fraction</p>\n</td>\n<td>\n<p>ACEI/ ARB + diuretic + beta-blocker (A+D+B)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pregnancy</p>\n</td>\n<td>\n<p>Labetalol, Nifedipine, methyldopa</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ACEi &ndash; Angiotensin-converting enzyme inhibitors</p>\n<p>ARB &ndash; Angiotensin II receptor blockers</p>\n<p>CCB &ndash; Calcium Channel Blockers</p><hr><h3>Related Pearl: Parenteral drugs used in hypertensive emergencies</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Drugs</strong></p>\n</td>\n<td>\n<p><strong>Contraindications</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Beta-blockers</p>\n</td>\n<td>Labetalol, esmolol, metoprolol</td>\n<td>\n<p>Heart block, systolic heart failure, asthma bradycardia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Calcium channel blockers</p>\n</td>\n<td>\n<p>Clevidipine, nicardipine</p>\n</td>\n<td>\n<p>Advanced aortic stenosis&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>D1 receptor agonist</p>\n</td>\n<td>Fenoldopam</td>\n<td>\n<p>Caution in glaucoma</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"3\">\n<p>Vasodilators</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Nitroglycerin</p>\n</td>\n<td>Pericardial tamponade</td>\n</tr>\n<tr>\n<td>\n<p>Nitroprusside</p>\n</td>\n<td>Relatively contraindicated in liver failure and renal failure&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Hydralazine</p>\n</td>\n<td>&nbsp;CAD, RHD</td>\n</tr>\n<tr>\n<td>\n<p>ACE inhibitors</p>\n</td>\n<td>\n<p>Enalaprilat</p>\n</td>\n<td>History of angioedema</td>\n</tr>\n<tr>\n<td>\n<p>Alpha-blocker</p>\n</td>\n<td>\n<p>Phentolamine, Urapidil</p>\n</td>\n<td>&nbsp;Aortic stenosis, AV shunt</td>\n</tr>\n<tr>\n<td>\n<p>Centrally acting sympatholytics</p>\n</td>\n<td>\n<p>Clonidine</p>\n</td>\n<td>Severe AV block, sick-sinus syndrome</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/8a4bcdecc8194bae9ef8a680f6175771.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1098",
      "difficulty": "medium"
    },
    {
      "text": "Identify the incorrect statement regarding carbapenems.",
      "choices": [
        {
          "id": 1,
          "text": "They act by inhibiting the cell wall synthesis."
        },
        {
          "id": 2,
          "text": "Enterococcus faecium is resistant to imipenem."
        },
        {
          "id": 3,
          "text": "Cilastatin is administered along with meropenem."
        },
        {
          "id": 4,
          "text": "Ertapenem has longer half life than imipenem."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Cilastatin</strong>, a dehydropeptidase inhibitor, is <strong>administered with imipenem</strong> (and not meropenem) to prevent its inactivation by renal dehydropeptidase.</p>\n<p>Meropenem, doripenem, and ertapenem are resistant to inactivation by the enzyme and hence do not need cilastatin.</p>\n<p>Other options:</p>\n<ul>\n<li>Carbapenems are structurally related to beta-lactams and act by <strong>inhibiting cell wall synthesis</strong>.</li>\n<li><em>Enterococcus faecium</em>, methicillin-resistant strains of staphylococci<em>, Clostridium difficile</em>, <em>Burkholderia cepacia</em>, and <em>Stenotrophomonas maltophilia</em> are resistant to imipenem.</li>\n<li><strong>Ertapenem has longer half-life</strong> than imipenem, meropenem and <strong>can be given as one daily dose</strong>.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0045",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs act via the mechanism depicted in the illustration shown below?<div class='question-desc-html'><ol>\n<li>Dobutamine</li>\n<li>Interferon</li>\n<li>Imatinib</li>\n<li>Atropine</li>\n<li>Verapamil</li>\n<li>Misoprostol</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "4, 5 and 6"
        },
        {
          "id": 2,
          "text": "1 and 3"
        },
        {
          "id": 3,
          "text": "1, 4 and 6"
        },
        {
          "id": 4,
          "text": "2 and 4 only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given illustration shows the <strong>G-protein-coupled receptor pathway</strong> for signalling. The drugs that function via this mechanism are <strong>dobutamine,</strong> propranolol, <strong>atropine, misoprostol,</strong> montelukast.&nbsp;</p>\n<p>Functional families of <strong>GPCRs</strong> include <strong>beta-adrenergic</strong> receptors, <strong>muscarinic cholinergic</strong> receptors, <strong>eicosanoid</strong> receptors, and <strong>thrombin</strong> receptors.</p>\n<p>G proteins act as inhibitory and excitatory because of differences in the alpha subunit.</p>\n<p>In general, Gs and Gq subtypes are excitatory whereas Gi is inhibitory.</p>\n<p><strong>Resting-state:</strong></p>\n<ul>\n<li>G protein heterotrimer consisting of alpha, beta and gamma subunits forms a complex with G-protein-coupled receptors at the intracellular domain. The extracellular domain of GPCR has the binding domain for hormones and G protein subunits do not directly bind them.<strong>&nbsp;</strong></li>\n<li><strong>The alpha subunit is bound to GDP&nbsp;</strong></li>\n</ul>\n<p><strong>Binding of ligand results in an activated state:&nbsp;</strong></p>\n<ul>\n<li>Alpha subunit undergoes a conformational change</li>\n<li>Release of GDP and binding of GTP</li>\n<li>GTP bound alpha subunit dissociates from beta-gamma subunit</li>\n<li><strong>Both alpha subunit and beta-gamma subunit </strong>bind to and <strong>regulate effectors&nbsp;only when they are separated&nbsp;</strong></li>\n</ul>\n<p>The illustration below shows the pathway.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/83e6ecc6f4954392abde621853e68007x1280x1346.JPEG\" alt=\"Explanation Image\"><p><strong>Other options</strong>:</p>\n<ul>\n<li><strong>Interferon</strong> acts through cytokine receptors, which belong to the structural family of transmembrane, non-enzymes.</li>\n<li><strong>Imatinib</strong> acts via the receptor tyrosine kinases, which belongs to the structural family of transmembrane enzymes.</li>\n<li><strong>Verapamil</strong> acts via the voltage-gated ion channel.</li>\n</ul><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d902400ccd9346d68492bfed78e061bb.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8137",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old male patient, who had undergone renal transplantation, presents to you with severe pain along the back of the leg above the heels. He reports that he has been taking some antibiotics without any doctor's prescription. You suspect Achilles tendon rupture. It is usually seen as a side effect of which of the following antibiotics?",
      "choices": [
        {
          "id": 1,
          "text": "Cotrimoxazole"
        },
        {
          "id": 2,
          "text": "Ciprofloxacin"
        },
        {
          "id": 3,
          "text": "Chloramphenicol"
        },
        {
          "id": 4,
          "text": "Doxycycline"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Achilles tendon rupture</strong> and<strong> tendinitis</strong> are associated side effects of<strong> quinolones</strong> like <strong>ciprofloxacin</strong>.</p>\n<p><strong>Elderly patients</strong> (&gt;60 years), patients on <strong>corticosteroids</strong>, and <strong>solid organ transplant recipients</strong> are at higher risk of developing this risk factor. </p>\n<p>Fluoroquinolones inhibit <strong>topoisomerase IV</strong> in <strong>gram-positive</strong> bacteria. Normally, during replication, to prevent excessive positive supercoiling of the strands, <strong>DNA gyrase</strong> nicks double-stranded DNA and introduces <strong>negative supercoils. </strong>Fluoroquinolones, by inhibiting DNA gyrase (in <strong>gram-negative</strong> bacteria), result in the production of damaged DNA. This is finally digested by exonucleases, resulting in <strong>bactericidal action.</strong></p>\n<p>Fluoroquinolones are used in the treatment of <strong>urinary tract infections</strong>, prostatitis, and gastrointestinal, and respiratory infections, and as a <strong>second-line</strong> drug in <strong>anti-tubercular therapy</strong>. They are <strong>avoided</strong> in <strong>children</strong> and <strong>pregnant women</strong>.</p>\n<p>Adverse effects of fluoroquinolones are <strong>arthralgia, t</strong><strong>endon rupture, </strong><em>Clostridium difficile</em> colitis, dysglycemia, prolonged QT interval, rashes, hallucinations, delirium, and seizures. </p><hr><h3>Related Pearl: Withdrawn fluoroquinolones and the associated adverse events</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><span><strong>Withdrawn Fluoroquinolones</strong></span></td>\n<td><span><strong>The Associated Adverse Events</strong></span></td>\n</tr>\n<tr>\n<td><span>Lomefloxacin and&nbsp;Gatifloxacin</span></td>\n<td><span>Phototoxicity, QTc prolongation</span></td>\n</tr>\n<tr>\n<td><span>Trovafloxacin</span></td>\n<td><span>Hepatotoxicity</span></td>\n</tr>\n<tr>\n<td><span>Gatifloxacin</span></td>\n<td><span>Hypoglycemia</span></td>\n</tr>\n<tr>\n<td><span>Grepafloxacin</span></td>\n<td><span>Cardiotoxicity</span></td>\n</tr>\n<tr>\n<td><span>Temafloxacin</span></td>\n<td><span>Immune hemolytic anemia</span></td>\n</tr>\n<tr>\n<td><span>Clinafloxacin</span></td>\n<td><span>Phototoxicity</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2716",
      "difficulty": "medium"
    },
    {
      "text": "What percentage of drug given will be left in the body after 3 half-lives, if the drug is eliminated by first order kinetics?",
      "choices": [
        {
          "id": 1,
          "text": "15"
        },
        {
          "id": 2,
          "text": "12.5"
        },
        {
          "id": 3,
          "text": "25"
        },
        {
          "id": 4,
          "text": "6.25"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The percentage of drug given will be left in the body if the drug eliminates by first-order kinetics after 3 half-lives is 12.5%.</p>\n<p>In first-order kinetics, the rate of elimination of the drug is directly proportional to the drug concentration.</p>\n<p>The rate of clearance remains constant.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Half-life</strong></td>\n<td><strong>Elimination (%)</strong></td>\n<td><strong>Drug left in the body</strong><strong>(%)</strong></td>\n</tr>\n<tr>\n<td>First</td>\n<td>50</td>\n<td> 50</td>\n</tr>\n<tr>\n<td>Second</td>\n<td>75</td>\n<td> 25</td>\n</tr>\n<tr>\n<td><strong>Third</strong></td>\n<td><strong>87.5</strong></td>\n<td><strong> 12.5</strong></td>\n</tr>\n<tr>\n<td>Fourth</td>\n<td>93.75</td>\n<td> 6.25</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5577",
      "difficulty": "easy"
    },
    {
      "text": "A 30-year-old man came with abdominal cramps, nausea, diarrhea for the past two days. He also reports having body pain, a runny nose, and teary eyes. On examination, his pupils are dilated and he frequently keeps yawning. On probing further, he reluctantly says that he uses recreational drugs. His blood pressure is 150/80 mm Hg and his heart rate is 110. Which of the following drugs is used for the maintenance therapy for his symptoms?",
      "choices": [
        {
          "id": 1,
          "text": "Methylmorphine"
        },
        {
          "id": 2,
          "text": "Methadone"
        },
        {
          "id": 3,
          "text": "Meperidine"
        },
        {
          "id": 4,
          "text": "Methylphenidate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Methadone</strong> is used for the maintenance of <strong>opioid (heroin) dependence</strong> as a <strong>substitute therapy</strong> because of its good oral bioavailability and long half-life. </p>\n<p>Methadone is substituted for opioids during detoxification to avoid withdrawal symptoms. Once stabilized, the dose is gradually reduced and the drug is stopped slowly over days. Because of its long half-life and accumulation in tissues, discontinuing the drug still results in low concentrations of the drug in plasma resulting in protracted withdrawal symptoms.</p>\n<p><strong>Treatment for opioid dependence</strong></p>\n<p><strong>Maintainance phase</strong>: to decrease the severity of withdrawal symptoms.</p>\n<ul>\n<li>Oral mu agonist: a safe substitute like methadone is given in a supervised manner to prevent withdrawal symptoms.</li>\n<li>Long acting agonist: buprenorphine can also be used.</li>\n<li>Clonidine, lofexidine reduce the withdrawal symptoms and anxiety</li>\n<li>Methadone, buprenorphine, LAAM(L-Alpha-Acetyl-Methadol): opioid agonists which reduce craving.</li>\n</ul>\n<p><strong>Relapse prevention phase</strong>:</p>\n<ul>\n<li>Naltrexone: An opioid antagonist that blocks opioid effects.</li>\n</ul>\n<p>Other options:</p>\n<p>Option A- <strong>Methylm</strong><strong>orphine</strong> (codeine)is an opioid agonist used for the relief of severe chronic cancer pain and suppression of cough. </p>\n<p>Option C- <strong>Meperidine</strong> belongs to a class of opioid analgesics and is similar to morphine. It is used to treat moderate to severe pain. </p>\n<p>Option D- <strong>Methylphenidate</strong> is a <strong>stimulant</strong> used to treat attention deficit hyperactivity disorder (ADHD).</p><hr><h3>Related Pearl: Substances of abuse</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Substance</strong></span></div>\n</td>\n<td>\n<div><span><strong>Withdrawal symptoms</strong></span></div>\n</td>\n<td>\n<div><span><strong>Intoxication features</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Alcohol</strong></span></div>\n</td>\n<td>\n<div><span>Tremors, delirium, seizures</span></div>\n</td>\n<td>\n<div><span>Blackouts, nystagmus and slurring of speech</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>BZD</strong></span></div>\n</td>\n<td>\n<div><span>Tremors,&nbsp;insomnia, anxiety</span></div>\n</td>\n<td>\n<div><span>Lethargy and drowsiness.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Opioid/ Heroin</strong></span></div>\n</td>\n<td>\n<div><span>Diarrhea,&nbsp;yawning, mydriasis,&nbsp;lacrimation, piloerection, cold turkey phenomenon</span></div>\n</td>\n<td>\n<div><span>Euphoria, depressed mental status, miosis, respiratory depression, constipation.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Nicotine/ Tobacco</strong></span></div>\n</td>\n<td>\n<div><span>Increased appetite</span></div>\n</td>\n<td>\n<div><span>Shows a biphasic pattern.&nbsp;</span></div>\n<div><span>Early stimulatory symptoms of vomiting, hypertension and tachycardia.&nbsp;</span><span>Later depressive symptoms of hypotension and bradycardia.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Cannabis</strong></span></div>\n</td>\n<td>\n<div><span>Irritability, sweating, tremors, decreased appetite</span></div>\n</td>\n<td>\n<div><span>Increased appetite, euphoria, conjunctival injection, dry mouth,&nbsp;</span><span>panic,&nbsp;</span><span>synesthesia, impaired time perception, amotivational&nbsp;syndrome, run amok and&nbsp;</span><span>flashbacks.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Amphetamine</strong></span></div>\n</td>\n<td>\n<div><span>Depressed mood, suicidal thoughts, unpleasant dreams</span></div>\n</td>\n<td>\n<div>\n<div><span>Acute:&nbsp;</span><span>Sympathetic&nbsp;</span><span>overactivity, paranoid hallucinatory syndrome, violent behavior, psychosis and diaphoresis.</span></div>\n</div>\n<div><span>Chronic: Runs &amp; crashes, choreiform movements, tooth decay. Can resemble schizophrenia.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Cocaine</strong></span></div>\n</td>\n<td>\n<div><span>Depressed mood, suicidal thoughts</span></div>\n</td>\n<td>\n<div><span>Acute: Sympathetic overactivity, agitation, euphoria, chest pain, seizures and mydriasis</span></div>\n<div><span>Chronic: Cocaine psychosis (Magnan sign) and black pigmentation of the tongue.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>LSD/ Haluccinogen</strong></span></div>\n</td>\n<td>\n<div><span>Nothing significant</span></div>\n</td>\n<td>\n<div>\n<div><span>Synesthesia, brisk tendon reflex, t</span>achycardia, hypertension, panic, ataxia, visual hallucinations, euphoria and dysphoria.</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Phencyclidine (PCP)</strong></span></div>\n</td>\n<td>\n<div><span>Nothing significant&nbsp;</span></div>\n</td>\n<td>\n<div>Tachycardia, hypertension, ataxia, hallucinations, violent behavior, dissociation, amnesia and nystagmus.</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9608",
      "difficulty": "medium"
    },
    {
      "text": "Drug of choice for ethylene glycol poisoning is",
      "choices": [
        {
          "id": 1,
          "text": "Ethanol"
        },
        {
          "id": 2,
          "text": "Fomepizole"
        },
        {
          "id": 3,
          "text": "Methanol"
        },
        {
          "id": 4,
          "text": "Disulfiram"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Intravenous fomepizole is the standard treatment for ethylene glycol poisoning</strong>. Intravenous ethanol is an alternative.</p>\n<p><strong>Fomepizole is administerd intravenously in methanol and ethylene glycol poisoning with a loading dose of 15 mg/kg</strong></p>\n<p><strong> Ethylene glycol poisoning</strong>:</p>\n<ul>\n<li>Ethylene glycol is used as heat exchangers, in antifreeze formulations and as industrial solvents.</li>\n<li>Ethylene glycol is relatively harmless but it forms metabolites like toxic aldehydes (converted to acids) and oxalate that are harmful.</li>\n<li>Inhibition of formation of toxic metabolites by adminitering fomepizole or ethanol is the mainstay of treatment.</li>\n</ul>\n<p><strong> Clinical features:</strong></p>\n<ul>\n<li>Initial excitation followed by CNS depression.</li>\n<li>After 4-12 hours, severe metabolic acidosis due to acid metabolites and lactate.</li>\n<li>Finally, renal insufficiency due to deposition of oxalate in renal tubules.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4085",
      "difficulty": "easy"
    },
    {
      "text": "A patient diagnosed with pulmonary tuberculosis was started on antitubercular therapy. Among the following antitubercular drugs given below, which of the following option selects all the drugs that have a bactericidal action?<div class='question-desc-html'><ol>\n<li>Isoniazid</li>\n<li>Rifampicin</li>\n<li>Pyrazinamide</li>\n<li>Ethambutol</li>\n<li>Streptomycin</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "1, 2, 3, 4"
        },
        {
          "id": 3,
          "text": "1, 4, 5"
        },
        {
          "id": 4,
          "text": "1, 2, 3, 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Ethambutol</strong> is the only <strong>bacteriostatic</strong> agent among the given options. All the options are examples of bactericidal drugs. Therefore, <strong>option D (1, 2, 3, 5)</strong> is the right answer.&nbsp;</p>\n<p><strong>Bactericidal</strong> antituberculosis agents (RIPS)</p>\n<ul>\n<li>R: Rifampicin (R)</li>\n<li>I: Isoniazid (H)</li>\n<li>P: Pyrazinamide (Z)</li>\n<li>S: Streptomycin (S)</li>\n</ul>\n<p>Treatment regimens for pulmonary tuberculosis and tuberculous meningitis consist of an <strong>initial 2-month phase of a 4-drug regimen</strong>, followed by a<strong> continuation phase</strong> of an additional <strong>4 months</strong> of isoniazid and rifampin for pulmonary tuberculosis.</p>\n<p><strong>Isoniazid</strong> is used for the treatment of <strong>tuberculosis</strong> (as part of combination therapy) or for <strong>latent</strong> <strong>tuberculosis</strong> infection (as monotherapy or part of combination therapy).&nbsp;The antimicrobial activity of INH is selective for mycobacteria, likely due to its ability to inhibit mycolic acid synthesis, which interferes with cell wall synthesis, thereby producing a bactericidal effect&nbsp;</p>\n<p><strong>Rifampicin</strong> is thought to inhibit bacterial DNA-dependent RNA polymerase, which appears to occur as a result of drug binding in the polymerase subunit deep within the DNA/RNA channel, facilitating direct blocking of the elongating RNA. Along with Isoniazid, Rifampicin is also given in both the<strong> initial phase and continuation phase</strong> of the treatment of TB.</p>\n<p><strong>Pyrazinamide</strong> is most commonly used for the treatment of active tuberculosis (TB) during the<strong> initial phase of therapy</strong>&nbsp;only(generally the first two months of treatment), in combination with other agents. The spectrum of pyrazinamide is<strong> relatively narrow</strong>; it demonstrates clinically significant antibacterial activity only against&nbsp;<em>Mycobacterium tuberculosis</em>&nbsp;and&nbsp;<em>Mycobacterium africanum</em>.</p>\n<p><strong>Streptomycin</strong> is an<strong> injectable drug,&nbsp;</strong>also a bactericidal drug used sometimes in the initial phase of treatment of pulmonary TB.</p>\n<p><strong>Ethambutol </strong>is the only drug in the initial phase which is an example of a <strong>bacteriostatic</strong> drug.&nbsp;There is evidence that the drug exerts its bacteriostatic activity by virtue of <strong>inhibition of arabinosyl transferase</strong>, an enzyme that polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent.</p><hr><h3>Related Pearl: General properties of the first line drugs in TB</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>First-line drugs</strong></span></div>\n</td>\n<td>\n<div><span><strong>Isoniazid</strong></span></div>\n</td>\n<td>\n<div><span><strong>Rifampicin</strong></span></div>\n</td>\n<td>\n<div><span><strong>Pyrazinamide</strong></span></div>\n</td>\n<td>\n<div><span><strong>Ethambutol</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Mechanism</strong></span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n<div><span>(Maximum)</span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n</td>\n<td>\n<div><span>Bacteriostatic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Location of Mycobacteria</strong></span></div>\n</td>\n<td>\n<div><span>Intracellular +&nbsp; Extracellular</span></div>\n</td>\n<td>\n<div><span>Intracellular +&nbsp; Extracellular</span></div>\n</td>\n<td>\n<div><span>Intracellular</span></div>\n</td>\n<td>\n<div><span>Extracellular</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Metabolism</strong></span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n<div><span>(Maximum)</span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n</td>\n<td>\n<div><span>Kidney</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p><hr><h3>Related Pearl: Classification of TB Patients Based on History of Treatment</h3><p><strong>New case</strong> is defined as a TB patient who had</p>\n<ul>\n<li><strong>Never taken</strong> ATT previously or</li>\n<li>Taken ATT for <strong>&lt; 1 month</strong></li>\n</ul>\n<p><strong>Previously treated Case :&nbsp;</strong>Patients who have <strong>received 1 month or more</strong> of Anti TB drugs in the past. These include:</p>\n<ol>\n<li><strong>Recurrent TB:&nbsp;</strong>A TB patient who <strong>had completed course of treatment</strong> <strong>/ declared cured</strong> and now presenting as microbiologically confirmed case</li>\n<li><strong>Treatment after failure:&nbsp;</strong>Patients who had been treated for TB and <strong>their treatment failed</strong> at the end of most recent course of treatment</li>\n<li><strong>Treatment after loss to follow up:&nbsp;</strong>A TB patient who had <strong>been treated &gt; 1 month on ATT</strong> and registered as l<strong>ost to follow up</strong> and now presenting as microbiologically confirmed case of TB</li>\n<li><strong>Other previously treated patients:&nbsp;</strong>Patients who had been previously treated but whose <strong>outcome is now unknown/undocumented</strong></li>\n</ol>\n<p><strong>Transferred in:&nbsp;</strong>A TB patient who has been received in a TB unit after having registered in another TB unit for treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8098",
      "difficulty": "easy"
    },
    {
      "text": "In which of the following drug toxicities is alkalinization of urine done?",
      "choices": [
        {
          "id": 1,
          "text": "Barbiturate"
        },
        {
          "id": 2,
          "text": "Amphetamine"
        },
        {
          "id": 3,
          "text": "Heparin"
        },
        {
          "id": 4,
          "text": "Morphine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Alkalinization</strong> of the<strong> urine</strong> is done in poisoning with acidic drugs such as <strong>barbiturates</strong>. When the urine is alkaline, weakly acidic drugs like barbiturates are present in <strong>highly ionized</strong> form and are <strong>excreted</strong> more<strong> rapidly.</strong></p>\n<p>When the tubular urine is made more alkaline, weak acids like barbiturates become highly ionized and are excreted to a greater extent. Similarly, acidification of urine increases the excretion of weak bases. This property is used in the management of drug overdose.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Drug</strong></td>\n<td><strong>Treatment of overdose</strong></td>\n</tr>\n<tr>\n<td>Weak acids<br />(e.g., phenobarbital, aspirin)</td>\n<td>Alkalinization of urine with <strong>sodium bicarbonate</strong></td>\n</tr>\n<tr>\n<td>Weak bases<br />(e.g., amphetamine)</td>\n<td>Acidification of urine with <strong>ammonium chloride</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4484",
      "difficulty": "medium"
    },
    {
      "text": "A 70 year old female presents to the OPD with symptoms of pain in both the knees since the past two years. She has been on calcium and vitamin D supplementation and is doing regular physical exercise. X-ray of the knee joint showed the following. Which would be the first line drug for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Strontium"
        },
        {
          "id": 2,
          "text": "Combined oral contraceptives"
        },
        {
          "id": 3,
          "text": "Raloxifene"
        },
        {
          "id": 4,
          "text": "Bisphosphonates"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Bisphosphonates are used in the <strong>first-line management </strong>of postmenopausal osteoporosis. X Ray shows periarticular osteopenia around the knee joint.</p>\n<p>Bisphosphonates are analogs of <strong>pyrophosphate</strong>. They specifically inhibit bone resorption and thus are very effective for the treatment of postmenopausal osteoporosis.</p>\n<p>Mechanism of action:</p>\n<p>Bisphosphonates concentrate at sites of <strong>active remodeling</strong>. They remain in the matrix until the bone is remodeled. Then, they are released in the acid environment of the resorption lacunae and induce apoptosis in osteoclasts.</p>\n<p><strong>Other Drugs:</strong></p>\n<ul>\n<li><strong>Denosumab -</strong> This is an antibody to the RANK ligand. It prevents the activation of RANK which is required for the proliferation of osteoclasts. Therefore, it decreases bone resorption.</li>\n<li><strong>Parathyroid hormone - Teriparatide</strong>&nbsp;is a recombinant parathyroid hormone analog. At low and intermittent doses, they can promote bone formation.</li>\n<li><strong>Selective estrogen receptor modulators (SERMs) -</strong> They act on the estrogen receptors and prevent bone resorption. Eg.&nbsp;<strong>raloxifene.</strong></li>\n<li><strong>Strontium ranelate -</strong> It is thought to increase bone formation and reduce bone resorption.</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/63ed9db46ba442268a3c257ff193966a.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1547",
      "difficulty": "easy"
    },
    {
      "text": "A 28-year-old woman gave birth to a child with the features shown in the given image. On examination, the child had brittle bones, and x-ray scans revealed stippled epiphyses. Which of the following drugs is most likely to be implicated in causing this teratogenic condition?",
      "choices": [
        {
          "id": 1,
          "text": "Alcohol"
        },
        {
          "id": 2,
          "text": "Topiramate"
        },
        {
          "id": 3,
          "text": "Warfarin"
        },
        {
          "id": 4,
          "text": "Lithium"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><span data-preserver-spaces=\"true\">The given image shows a depressed nasal bridge (saddle nose). This image along with the stippling of bone epiphyses points to <strong>fetal warfarin syndrome </strong>or<strong> warfarin embryopathy</strong>. </span></p>\n<p><strong><span data-preserver-spaces=\"true\">Features:</span></strong></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">Repeated abortions</span></li>\n<li><span data-preserver-spaces=\"true\">CNS abnormalities</span></li>\n<li><span data-preserver-spaces=\"true\">Depressed nasal bridge/absent nasal bone/saddle nose at birth</span></li>\n<li><span data-preserver-spaces=\"true\">Bleeding diathesis at birth</span></li>\n<li><span data-preserver-spaces=\"true\">Growth retardation - hypoplasia of nose, eye sockets, and long bones with stippling of epiphyses </span></li>\n</ul>\n<p><span data-preserver-spaces=\"true\"><strong>Anticoagulation in pregnancy:</strong></span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">Warfarin: Although safe for the mother, it can lead to </span><strong><span data-preserver-spaces=\"true\">warfarin embryopathy</span></strong><span data-preserver-spaces=\"true\">, miscarriage, IUGR, and stillbirths.</span></li>\n<li><span data-preserver-spaces=\"true\">Heparin: It is safe for the fetus</span><span data-preserver-spaces=\"true\"> but is less effective than warfarin.</span></li>\n<li><span data-preserver-spaces=\"true\">LMWH: It is inadequate, and ACOG does not recommend its use in pregnant women with prosthetic heart valves.</span></li>\n</ul>\n<table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Period of gestation</strong></p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Anticoagulant</strong></p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Till 12 completed weeks</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">LMWH or UFH</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">13 to 36 weeks</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Warfarin</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">36 weeks to 6 hours before delivery</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">LMWH or UFH</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">6 hours after vaginal and 24 hours after cesarian section</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">LMWH or UFH (ACOG recommendation)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span data-preserver-spaces=\"true\">If delivery occurs while the anticoagulant is still effective, and excessive bleeding happens, then <strong>protamine sulfate</strong> is given intravenously. </span></p>\n<p><span data-preserver-spaces=\"true\">Anticoagulation of pregnant women:</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">The patient taking warfarin should discontinue it as soon as pregnancy is diagnosed and replace it with </span><strong><span data-preserver-spaces=\"true\">heparin 5,000 units twice daily subcutaneously up to the 12th week of gestation</span></strong><span data-preserver-spaces=\"true\">. </span></li>\n<li><span data-preserver-spaces=\"true\">Heparin is then replaced by </span><strong><span data-preserver-spaces=\"true\">a warfarin tablet of 3 mg daily</span></strong><span data-preserver-spaces=\"true\"> to be taken at the same time each day and continued </span><strong><span data-preserver-spaces=\"true\">up to 36 weeks </span></strong>in patients with a high risk of thrombosis.</li>\n<li><span data-preserver-spaces=\"true\">Thereafter, warfarin is replaced by </span><strong><span data-preserver-spaces=\"true\">heparin, which is discontinued 6 hours</span></strong><span data-preserver-spaces=\"true\"> just before delivery.</span></li>\n<li><span data-preserver-spaces=\"true\">Heparin (unfractionated or LMWH) is restarted 6 hours after vaginal delivery and 24 hours after the cesarean section.</span></li>\n<li><span data-preserver-spaces=\"true\">Unfractionated heparin (UFH), LMWH, and warfarin therapy are </span><strong><span data-preserver-spaces=\"true\">not contraindicated</span></strong><span data-preserver-spaces=\"true\"> in breastfeeding.</span></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0d669e35bc1e4139bd255e4387c48c61x1280x1476.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Teratogenic drugs and the birth defects</h3><table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Adverse effects</strong></td>\n</tr>\n<tr>\n<td>Penicillamine</td>\n<td>Cutis laxa syndrome</td>\n</tr>\n<tr>\n<td><strong>Lithium</strong></td>\n<td><strong>Ebstein anomaly</strong></td>\n</tr>\n<tr>\n<td>Isotretinoin</td>\n<td>Facial-ear anomalies, heart disease, CNS anomalies</td>\n</tr>\n<tr>\n<td>Progesterone</td>\n<td>Masculinization of the female fetus</td>\n</tr>\n<tr>\n<td>Quinine</td>\n<td>Abortion, thrombocytopenia, deafness</td>\n</tr>\n<tr>\n<td>Topiramate</td>\n<td>Cleft lip</td>\n</tr>\n<tr>\n<td><strong>Valproate</strong></td>\n<td>Spina bifida, limb defects, <strong>autism spectrum disorder</strong>, facial and cardiac anomalies, <strong>Coarctation of the aorta</strong>, Aortic stenosis, Pulmonary atresia, Ventricular Septal Defect. </td>\n</tr>\n<tr>\n<td><strong>Vitamin D</strong></td>\n<td><strong>Supravalvular aortic stenosis</strong></td>\n</tr>\n<tr>\n<td><strong>Warfarin</strong></td>\n<td>Fetal bleeding, <strong>hypoplastic nasal structures</strong></td>\n</tr>\n<tr>\n<td><strong>Statins</strong></td>\n<td>Vertebral, anal, cardiac, tracheoesophageal fistula, renal, arterial, limb (<strong>VACTERAL</strong>) defects</td>\n</tr>\n<tr>\n<td><strong>Phenytoin</strong></td>\n<td>Ventricular septal defect, Atrial Septal Defect, Coarctation of the aorta, Patent Ductus Arteriosus</td>\n</tr>\n<tr>\n<td>ACE inhibitors and ARBs</td>\n<td>\n<p>Hypoplasia of organs, anuria, irreversible renal failure</p>\n</td>\n</tr>\n<tr>\n<td>Carbimazole and Methimazole</td>\n<td> \n<p>Choanal atresia, aplasia cutis, tracheoesophageal fistula and fetal goiter</p>\n</td>\n</tr>\n<tr>\n<td>Alcohol</td>\n<td>Atrial Septal Defect, Ventricular Septal Defect</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Classification of Anticoagulants</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b14dd7e06cd44c95a1d5289e3a32ad8ax1280x1944.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Classification of anticoagulants</strong></td>\n</tr>\n<tr>\n<td>1) Vitamin K antagonist</td>\n<td>Warfarin</td>\n</tr>\n<tr>\n<td>2) Direct thrombin inhibitors (DTI)&nbsp;&nbsp;&nbsp;</td>\n<td>\n<p><strong>Parenteral:&nbsp;Monovalent</strong> DTI-&nbsp;Argatroban</p>\n<p><strong>Bivalent</strong> DTI- Lepirudin, Desirudin, Bivalirudin</p>\n<p><strong>Oral</strong>:&nbsp;Dabigatran&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>3) Indirect thrombin inhibitors&nbsp;</td>\n<td>\n<p>Unfractionated heparin</p>\n<p>Low molecular weight heparins:&nbsp;Enoxaparin, Dalteparin, Tinzaparin, Nadroparin</p>\n</td>\n</tr>\n<tr>\n<td>4) Indirect factor Xa inhibitors</td>\n<td>Fondaparinux</td>\n</tr>\n<tr>\n<td>5) <strong>Oral</strong> Direct factor Xa inhibitors</td>\n<td>Rivaro<strong>xa</strong>ban,Api<strong>xa</strong>ban, Edo<strong>xa</strong>ban,Betri<strong>xa</strong>ban</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/21168bb11bea4a9e9e9a38278b618a9f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD9578",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is indicated for paroxysmal supraventricular tachycardia?",
      "choices": [
        {
          "id": 1,
          "text": "Amiodarone"
        },
        {
          "id": 2,
          "text": "Streptokinase"
        },
        {
          "id": 3,
          "text": "Diltiazem"
        },
        {
          "id": 4,
          "text": "Adenosine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Among the given options, adenosine is the drug of choice for paroxysmal supraventricular tachycardia.</p>\n<ul>\n<li>Adenosine is an ultra-short acting drug with half-life being <strong>less than 10 seconds</strong>.</li>\n<li>It activates an <strong>inward rectifier K+ current</strong> along with <strong>inhibition of calcium current</strong>. The results of these actions are marked hyperpolarization and suppression of calcium- dependent action potentials.</li>\n<li>When given as a <strong>bolus dose</strong>, adenosine directly inhibits <strong>AV nodal conduction</strong> but has lesser effects on the SA node.</li>\n<li>Currently, Adenosine is used for prompt conversion of <strong>paroxysmal supraventricular tachycardia</strong> to sinus rhythm because of its high efficacy (90–95%) and very short duration of action. It is usually given in a bolus dose of <strong>6 mg f</strong>ollowed by a dose of <strong>12 mg</strong>, if required.</li>\n<li><strong>Flushing, shortness of breath and chest burning</strong> are some of its adverse effects.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6778",
      "difficulty": "easy"
    },
    {
      "text": "A middle-aged hypertensive man presents with acute onset pain and swelling on his toe over the left foot. Local examination showed a swelling over the first metatarsophalangeal joint of the left foot, as shown below. Which of the following antihypertensive drugs can be safely administered to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Losartan"
        },
        {
          "id": 2,
          "text": "Atenolol"
        },
        {
          "id": 3,
          "text": "Hydrochlorothiazide"
        },
        {
          "id": 4,
          "text": "Furosemide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario with <strong>acute onset pain</strong> and <strong>swelling</strong> <span data-preserver-spaces=\"true\">over the <strong>first metatarsophalangeal joint </strong>of the <strong>left foot </strong></span>suggests the diagnosis of <strong>acute gout</strong>. <strong>Losartan<span data-preserver-spaces=\"true\"> </span></strong><span data-preserver-spaces=\"true\">can be <strong>safely administered</strong> to this patient as it is a <strong>uricosuric drug</strong>.</span></p>\n<p><strong>Losartan</strong> is competitive <strong>angiotensin I (AT1) receptor antagonist</strong>, which binds to the AT<sub>1</sub> receptor with high affinity. Uses of losartan are:</p>\n<ul>\n<li>Antihypertensive</li>\n<li>Renoprotective drug in diabetes mellitus</li>\n<li>Stroke prophylaxis</li>\n<li>Portal hypertension in cirrhosis without compromising renal function</li>\n<li>Anti-aggregant as it is a competitive antagonist of the thromboxane A2 receptor </li>\n<li><strong>Uricosuric drug</strong> as it inhibits reabsorption and actively secretes uric acid in the proximal convoluted tubule</li>\n</ul>\n<p><span data-preserver-spaces=\"true\">Adverse effects include fetopathic potential, hypotension, renal insufficiency, and hyperkalemia. </span></p>\n<p><span data-preserver-spaces=\"true\">Other options:</span></p>\n<p><span data-preserver-spaces=\"true\">Option B: <strong>Atenolol</strong> is a <strong>beta blocker</strong> that has been proven to increase serum uric acid levels; hence, it is avoided.</span></p>\n<p><span data-preserver-spaces=\"true\">Option C: <strong>Hydrochlorothiazide </strong>is a <strong>thiazide diuretic; </strong>it is not used in patients with gout as it increases the uric acid level.</span></p>\n<p><span data-preserver-spaces=\"true\">Option D: <strong>Furosemide</strong> is a <strong>loop diuretic</strong> that causes hyperuricemia due to increased reabsorption of uric acid. It is </span><span data-preserver-spaces=\"true\">not used in patients with gout.</span></p><hr><h3>Related Pearl: Drugs precipitating Gout</h3><p>Drugs that precipitate gout are-</p>\n<p><strong>C</strong>yclosporine or cancer drugs<br /><strong>A</strong>spirin (low dose)<br /><strong>N</strong>iacin<br /><strong>T</strong>hiazide<br /><strong>L</strong>asix (furosemide)<br /><strong>E</strong>thambutol<br /><strong>A</strong>lcohol<br /><strong>P</strong>yrazinamide</p>\n<p>Mnemonic for drugs precipitating gout is '<strong>CANT LEAP</strong>'</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/168a64855ada4af7a5a6837afe6ccae5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4950",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statement best describes a partial agonist?",
      "choices": [
        {
          "id": 1,
          "text": "High affinity and high intrinsic activity"
        },
        {
          "id": 2,
          "text": "High affinity and low intrinsic activity"
        },
        {
          "id": 3,
          "text": "Low affinity and high intrinsic activity"
        },
        {
          "id": 4,
          "text": "High affinity and zero intrinsic activity"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Partial agonists have <strong>high affinity and low intrinsic activity.</strong></p>\n<p>According to the <strong>receptor occupation theory</strong>, the ability of a drug to bind to a receptor is its <strong>affinity,</strong> and the ability to induce functional change in the receptor is designated as the<strong> intrinsic activity (IA)</strong> of the drug. These 2 properties are<strong> independent</strong> of each other.</p>\n<ul>\n<li><strong>Full agonists</strong>: These agents have both affinity and maximum intrinsic activity. Examples are histamine, adrenaline, etc.</li>\n<li><strong>Partial agonists</strong>: They have affinity but submaximal intrinsic activity. e.g pentazocine on &micro; opiod receptors.</li>\n<li><strong>Inverse agonists</strong> are drugs that have an affinity for a receptor but the intrinsic activity is opposite to that of an agonist. Eg: chlorpheniramine on H1 receptors.</li>\n<li><strong>Competitive antagonists</strong>: These agents have affinity and no intrinsic activity. Eg:propanolol, atropine etc.</li>\n</ul>\n<p>The intrinsic activities of the above groups of drugs are given below:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type of drugs</strong></p>\n</td>\n<td>\n<p><strong>Intrinsic activity</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Agonists</p>\n</td>\n<td>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Partial agonists</p>\n</td>\n<td>\n<p>&gt;0 to &lt;1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Competitive antagonists</p>\n</td>\n<td>\n<p>0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inverse agonists</p>\n</td>\n<td>\n<p>&lt;0 to -1</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1153",
      "difficulty": "easy"
    },
    {
      "text": "On observing the presence of Fleischer vortex(whorl keratopathy) during the ocular examination of a patient, you would expect to find a history of intake of which of the following drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Leflunomide"
        },
        {
          "id": 2,
          "text": "Chloroquine"
        },
        {
          "id": 3,
          "text": "Primaquine"
        },
        {
          "id": 4,
          "text": "Apraclonidine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Chloroquine</strong>, an anti-malarial drug may get deposited in the cornea leading to whorl-like opacity in corneal epithelium called <strong>cornea verticillata/vortex keratopathy/ Fleisher vortex/ whorl keratopathy.</strong></p>\n<p>Chloroquine - ocular toxicity:</p>\n<ul>\n<li>On short-term therapy, chloroquine causes<strong> blurring of vision</strong> and <strong>diplopia,</strong> which are <strong>reversible</strong> by stopping the drug.</li>\n<li>Long-term (&gt;5 years) use of high doses of chloroquine causes <strong>keratopathy, pigmentary retinopathy,</strong> and <strong>optic</strong> <strong>atrophy</strong>.</li>\n<li><strong>Hydroxychloroquine</strong> has lower ocular toxicity compared to chloroquine.</li>\n<li>The maximum permissible dosage of chloroquine is <strong>6mg/Kg&nbsp;</strong>in 24 hours, while that of hydroxychloroquine is <strong>4.5mg/Kg</strong>&nbsp;in 24 hours.</li>\n</ul>\n<p>Long-term treatment with chloroquine may sometimes cause whorl-like opacity in corneal epithelium called <strong>cornea verticillata.</strong></p>\n<p><strong>Other causes of corneal verticillata:&nbsp;</strong></p>\n<ul>\n<li>Fabry&rsquo;s disease</li>\n<li>Amiodarone</li>\n<li>Chloroquine</li>\n<li>Hydroxychloroquine</li>\n<li>Indomethacin</li>\n<li>Phenothiazines</li>\n<li>Atovaquone</li>\n</ul>\n<p>Other side effects of Chloroquine are:</p>\n<div id=\"xhash_F149750\" class=\"block adr drugH1Div\">\n<ul>\n<li>Gastrointestinal (common): <strong>Abdominal cramps</strong>, anorexia, diarrhea, nausea, vomiting</li>\n<li>Cardiovascular: Atrioventricular block, bundle branch block, cardiac arrhythmia, cardiac failure, cardiomyopathy, ECG changes, hypotension, torsades de pointes, ventricular fibrillation, ventricular tachycardia</li>\n<li>Dermatologic: Alopecia, bleaching of hair, blue-grey skin pigmentation, erythema multiforme, exacerbation of psoriasis, urticaria, etc</li>\n<li>Endocrine &amp; metabolic: Exacerbation of porphyria, severe hypoglycemia</li>\n<li>Hematologic &amp; oncologic: Agranulocytosis (reversible), aplastic anemia, hemolytic anemia (in G6PD-deficient patients), neutropenia, pancytopenia, thrombocytopenia</li>\n<li>Hepatic: Hepatitis, increased liver enzymes</li>\n<li>Nervous system: Agitation, anxiety, confusion, decreased deep tendon reflex, delirium, depression, extrapyramidal reaction (dystonia, dyskinesia, protrusion of the tongue, torticollis) etc</li>\n<li>Neuromuscular &amp; skeletal: Asthenia, myopathy, neuromuscular disease, proximal myopathy</li>\n<li><strong>Ophthalmic</strong>: Accommodation disturbances, blurred vision, corneal opacity (reversible), macular degeneration (may be irreversible), maculopathy (may be irreversible), night blindness, <strong>retinal pigment changes (bull&rsquo;s eye appearance)</strong>, retinopathy (including irreversible changes in long-term or high-dose therapy), transient scotomata, visual field defect (paracentral scotomas)</li>\n</ul>\n</div>\n<div id=\"xhash_F149765\" class=\"block coi drugH1Div\">A bilateral whorl-like corneal pattern of cream-colored lines,&nbsp;as shown in the image below, is called&nbsp;corneal verticillata.</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/13d63b3e86584ea7808ec513c72177ffx720x431.JPEG\" alt=\"Explanation Image\"><p>Image below shows&nbsp;<strong>increased fluorescence in the macular area</strong> and round-shaped blocked fluorescence in the central fovea. It is likely due chloroquine&nbsp;toxicity.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b5c17b2e4975432f8879b5c8db3e3577x720x264.PNG\" alt=\"Explanation Image\"><p>Other options:</p>\n<ul>\n<li>Commonly seen side effects with leflunomide are headache,&nbsp;alopecia, skin rash, diarrhea and nausea.</li>\n<li id=\"xhash_F213221\" class=\"block adr drugH1Div\">\n<p>Commonly seen side effects with primaquine are gastrointestinal, cardiac arrhythmia, dizziness,&nbsp;pruritus, skin rash, anemia, hemolytic anemia (in patients with G6PD deficiency), leukopenia and methemoglobinemia (in NADH-methemoglobin reductase-deficient individuals)</p>\n</li>\n<li class=\"block adr drugH1Div\">\n<p>Commonly seen side effects with apraclonidine are gastrointestinal, xerostomia, eye discomfort, eye pruritus and ocular hyperemia.</p>\n</li>\n</ul><hr><h3>Related Pearl: Treatment of Malaria</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine</strong> 25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT/ Severe malaria </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Quinine </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong></p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st&nbsp;</sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>ACT:&nbsp;</strong>artemisinin-based combination therapy</p>\n<p><strong>AL:</strong>&nbsp;artemether-lumefantrine</p>\n<p><strong>SP</strong>: Sulfadoxine-<wbr />Pyrimethamine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8077",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is an indication for alprostadil use?",
      "choices": [
        {
          "id": 1,
          "text": "Use as an abortifacient"
        },
        {
          "id": 2,
          "text": "Closure of patent ductus arteriosus"
        },
        {
          "id": 3,
          "text": "Maintaining the patency of ductus arteriosus"
        },
        {
          "id": 4,
          "text": "Induction of labor"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Alprostadil</strong> is used for the temporary <strong>maintenance</strong> <strong>of the patency of the ductus arteriosus</strong> in neonates, keeping the ductus arteriosus open.&nbsp;</p>\n<p>Alprostadil is a natural <strong>PGE<sub>1</sub></strong> analog. PGE<sub>1</sub> is a potent and specific relaxant of ductal smooth muscle.</p>\n<p>The ductus arteriosus (the fetal connection between the pulmonary artery and the descending aorta) is <strong>functionally closed at 10-15 hrs</strong> after birth and <strong>anatomically closed at 10-21 days&nbsp;</strong>after birth.</p>\n<p>Survival of newborns with certain heart lesions such as <strong>coarctation of the aorta, hypoplastic left heart syndrome,&nbsp;</strong> and<strong> transposition of great vessels</strong> depends on the patency of ductus arteriosus. Closure of ductus arteriosus in such conditions can lead to hypoperfusion, severe hypoxia, and cyanosis. Maintaining the patency of ductus arteriosus in neonates is essential in some congenital heart diseases before corrective surgery is performed, and alprostadil is used for this purpose.</p>\n<p>Alprostadil is also used in the treatment of critical limb ischemia, <strong>erectile dysfunction,</strong> and pulmonary hypertension. Treatment with alprostadil results in an<strong> improvement</strong> in ulcers, pain, and limb salvage rates in <strong>critical limb ischemia</strong> patients.</p>\n<p><strong>Side effects</strong> of alprostadil include pain, bruising, and <strong>priapism</strong>. If priapism occurs, the patient will need urgent medical attention, which might include aspiration of blood, surgical shunt, or intracavernosal injection of phenylephrine for cavernosal vasoconstriction.</p>\n<p>PGE<sub>1</sub> analogs like <strong>alprostadil, misoprostol,</strong> and<strong> rioprostil</strong> can also be used to keep the ductus open and support systemic blood supply.</p>\n<p>Other options:</p>\n<p>Option A: <strong>PGF<sub>2&alpha;</sub></strong> analog <strong>carboprost</strong> is used as an <strong>abortifacient</strong> in the second trimester.</p>\n<p>Option B: <strong>Indomethacin </strong>a non-steroidal anti-inflammatory drug is used for the<strong> closure of patent ductus arteriosus</strong>.</p>\n<p>Option D:<strong> Dinoprostone </strong>(<strong>PGE<sub>2</sub></strong>) can be used for the&nbsp;<strong>induction of labor</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1545",
      "difficulty": "easy"
    },
    {
      "text": "A 10-year-old girl was brought with complaints of vomiting and altered consciousness. She was recently diagnosed with an influenza infection and was started on an antipyretic for fever. Laboratory tests showed increased levels of liver enzymes but normal serum bilirubin levels. What could have been the prescribed antipyretic in this case?",
      "choices": [
        {
          "id": 1,
          "text": "Mefenamic acid"
        },
        {
          "id": 2,
          "text": "Aspirin"
        },
        {
          "id": 3,
          "text": "Ibuprofen"
        },
        {
          "id": 4,
          "text": "Acetaminophen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">The clinical history suggests an<strong> adverse reaction</strong> to the given antipyretic medication and describes <strong>Reye's syndrome</strong>. Reye's syndrome can be precipitated in children with <strong>viral infection</strong> and concomitant use of <strong>salicylates</strong> like <strong>aspirin</strong>.</p>\n<p class=\"p1\">Reye syndrome is an <strong>acute encephalopathy</strong> that may follow a viral upper respiratory tract infection (influenza or varicella). It is precipitated in a genetically susceptible person by the interaction between viral infection and exposure to&nbsp;<strong>salicylates</strong> and/or antiemetics.</p>\n<p class=\"p1\">Clinically children present with acute onset <strong>vomiting</strong> and features of <strong>encephalopathy</strong> like delirium, altered consciousness, confusion, and lethargy.</p>\n<p class=\"p1\"><strong>Liver dysfunction</strong> is present in all cases and presents with coagulopathy and laboratory evidence of elevated serum levels of aspartate aminotransferase, alanine aminotransferase, and ammonia. But, <strong>bilirubin</strong> levels remain <strong>normal</strong> and the patient does not develop jaundice.</p>\n<p class=\"p1\">A <strong>biopsy</strong> of the liver in a patient with Reye's syndrome shows <strong>microvesicular infiltration</strong> of <strong>fat</strong> in the <strong>hepatocytes.&nbsp;</strong>Reye syndrome is a life-threatening adverse effect, and patients must also be screened for fatty acid oxidation and fatty acid transport defects.</p>\n<p>Another salicylate medication that risks the development of Reye's syndrome is&nbsp;<strong>bismuth subsalicylate</strong>.</p>\n<p>Other options:</p>\n<p><strong>Mefenamic acid</strong>, <strong>ibuprofen</strong>, and <strong>acetaminophen </strong>are non-steroidal anti-inflammatory drugs that can be used as antipyretics in children and are not associated with the development of Reye's syndrome.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1853",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old male patient has been prescribed a drug that catalyzes the enzymatic oxidation of uric acid into allantoin for the treatment of his chronic gout. What is this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Colchicine"
        },
        {
          "id": 2,
          "text": "Febuxostat"
        },
        {
          "id": 3,
          "text": "Pegloticase"
        },
        {
          "id": 4,
          "text": "Allopurinol"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The drug that catalyzes the enzymatic oxidation of uric acid into allantoin for the treatment of chronic gout is<strong> pegloticase. </strong></p>\n<p>Pegloticase is a <strong>pegylated uricase</strong> (urate oxidase) that catalyzes the enzymatic oxidation of <strong>uric acid into allantoin</strong>, which is a more soluble and inactive metabolite. It is used in the treatment of <strong>severe</strong>, <strong>refractory chronic gout</strong> or in cases where other urate-lowering therapies are contraindicated. The efficacy of this drug gets lowered if antibodies are produced against the drug, which occurs in many patients. This also increases the risk of infusion reactions. </p>\n<div class=\"page\" title=\"Page 711\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 711\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Rasburicase</strong> is a <strong>recombinant uricase</strong>. It is indicated for the initial management of elevated plasma uric acid levels in patients with malignancies who are on chemotherapy. The efficacy is limited by the production of antibodies to the drug.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Gout</strong> occurs due to the precipitation of urate crystals in the tissues with a subsequent inflammatory response. In an acute episode of gout, there is painful distal monoarthritis which can lead to joint destruction, subcutaneous tophi, and renal calculi. Management of gout includes:</p>\n<div class=\"page\" title=\"Page 708\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Reduction of pain and inflammation: NSAIDs, colchicine, glucocorticoids</li>\n<li>Inhibition of the formation of urate: Allopurinol, febuxostat</li>\n<li>Promotion of urate excretion: Probenecid, lesinurad</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n<p>Other options: </p>\n<p>Option A: <strong>Colchicine</strong> acts by <strong>preventing the polymerization of microtubules by tubulin</strong>, this <strong>reduces neutrophil recruitment</strong> to inflamed tissue and also <strong>decreases the secretion of chemotactic factors</strong> by activated neutrophils. Overall reducing the inflammatory response.</p>\n<p>Option B: <strong>Febuxostat</strong> is a <strong>xanthine oxidase inhibitor</strong> approved for the <strong>treatment of hyperuricemia</strong> in patients with gout.</p>\n<p>Option D: <strong>Allopurinol</strong> by <strong>inhibiting the xanthine oxidase</strong> enzyme prevents the conversion of xanthine to uric acid.</p><hr><h3>Related Pearl: Drugs precipitating Gout</h3><p>Drugs that precipitate gout are-</p>\n<p><strong>C</strong>yclosporine or cancer drugs<br /><strong>A</strong>spirin (low dose)<br /><strong>N</strong>iacin<br /><strong>T</strong>hiazide<br /><strong>L</strong>asix (furosemide)<br /><strong>E</strong>thambutol<br /><strong>A</strong>lcohol<br /><strong>P</strong>yrazinamide</p>\n<p>Mnemonic for drugs precipitating gout is '<strong>CANT LEAP</strong>'</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2289",
      "difficulty": "medium"
    },
    {
      "text": "The image below shows the life cycle of a virus. Which of the following drugs acts at step 5?",
      "choices": [
        {
          "id": 1,
          "text": "Raltegravir"
        },
        {
          "id": 2,
          "text": "Enfuvirtide"
        },
        {
          "id": 3,
          "text": "Tenofovir"
        },
        {
          "id": 4,
          "text": "Zidovudine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Step 5 in the given life cycle shows the <strong>integration</strong> of the <strong>viral DNA</strong> into the <strong>host genome</strong>. <strong>Raltegravir</strong> is an integrase inhibitor and is active against both <strong>HIV-1</strong> and <strong>HIV-2</strong>. It can be used in <strong>adults</strong> and <strong>children</strong>&nbsp;<strong>&gt;1 month old.&nbsp;</strong></p>\n<p>It is advised for patients to consume <strong>antacids</strong> and <strong>sucralfate,</strong> 6 hours before or 2 hours after raltegravir intake.</p>\n<p>It may cause <strong>headaches, nausea, weakness</strong> and <strong>fatigue.</strong> Rarely, it can lead to drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.</p>\n<p>The steps involved in the lifecycle of HIV as given in the image are described as follows:</p>\n<ul>\n<li>Step 1: Binding of HIV-1 to the cell membrane of a CD4+ cell</li>\n<li>Step 2: HIV-1 enters the cell via interaction with the membrane glycoproteins</li>\n<li>Step 3: Reverse transcription of the viral genetic material using the virus' reverse transcriptase enzyme</li>\n<li>Step 4: The HIV-1 genome travels into the nucleus</li>\n<li>Step 5: The viral genome integrates into the host's DNA through the integrase enzyme</li>\n<li>Step 6: The HIV-1 proviral genome undergoes transcription with the host DNA</li>\n<li>Step 7: The viral messenger RNA (mRNA) undergoes translation to produce new viral proteins</li>\n<li>Steps 8 and 9: Assembly and maturation of the virion</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61c1774501b74506af250308d493739ax850x704.PNG\" alt=\"Explanation Image\"><p>Other options:</p>\n<p>Option B: Enfuvirtide acts at <strong>step 2</strong> in the given image. It blocks gp41 of the cell membrane and <strong>blocks the entry</strong> of the virus into the cell. It prevents the free viral particles from invading new CD4+ cells. It is effective against <strong>HIV-1.</strong></p>\n<p>Option C: Tenofovir acts at <strong>step 3</strong> in the given image. It is a nucleotide reverse transcriptase inhibitor (NRTI) that is effective against <strong>HIV-1,2</strong> and <strong>hepatitis B</strong> infections. It is used in adults and <strong>children &gt;2 years old. </strong>It can also be used for<strong> pre-exposure prophylaxis.&nbsp;</strong></p>\n<p>Option D: Zidovudine also acts at <strong>step 3</strong> in the given image. It is an NRTI and is effective against <strong>HIV-1,2</strong> and <strong>Human T-cell Lymphoma Virus (HTLV).</strong> It can be used in adults and children. It can also be used to prevent <strong>mother-to-child transmission.</strong></p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p><hr><h3>Related Pearl: Opportunistic Infections/HIV related conditions and ART initiation</h3><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action&nbsp;</td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia)&nbsp;</td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems)&nbsp;</td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment&nbsp;</td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b656eec2969545cab6981b79ab874ed5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7222",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs acts through the receptor marked in the given image?",
      "choices": [
        {
          "id": 1,
          "text": "Abciximab"
        },
        {
          "id": 2,
          "text": "Tirofiban"
        },
        {
          "id": 3,
          "text": "Ticlopidine"
        },
        {
          "id": 4,
          "text": "Eptifibatide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ticlopidine </strong>acts through the <strong>ADP receptor </strong>of the platelet and prevents its recruitment and activation.</p>\n<p><strong>Other drugs that act through the ADP receptor are:</strong></p>\n<ul>\n<li>Clopidogrel</li>\n<li>Prasugrel</li>\n<li>Cangrelor</li>\n<li>Ticagrelor</li>\n</ul>\n<p><strong>Drugs that act through GPIIb/IIIa are:</strong></p>\n<ul>\n<li>Abciximab</li>\n<li>Tirofiban</li>\n<li>Eptifibatide</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c09cde7947f64b44a589f3cc2e9221a7x1279x1689.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/89aaa2869da74867b1d5a9f2879c5d54.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC8549",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old male patient came to the hospital with vomiting. He was prescribed metoclopramide, following which he developed spasms of facial muscles, difficulty in speech, and torticollis. Which of the following drugs is indicated for the treatment of these symptoms?",
      "choices": [
        {
          "id": 1,
          "text": "Phenelzine"
        },
        {
          "id": 2,
          "text": "Diphenhydramine"
        },
        {
          "id": 3,
          "text": "Chlorpromazine"
        },
        {
          "id": 4,
          "text": "Prochlorperazine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In this case, the patient has developed symptoms of<strong> dystonia </strong>due to <strong>metoclopramide. Diphenhydramine </strong>is used in <strong>drug-induced dystonia</strong>.</p>\n<p>Metoclopramide has<strong> </strong>dopamine receptor antagonist, 5HT4 agonist, and 5HT3 antagonist properties. It is indicated in patients with <strong>gastroparesis</strong> and is also used in <strong>reducing nausea</strong> and vomiting that often accompany GI dysmotility syndromes.</p>\n<p><strong>Dopamine</strong> receptor <strong>antagonist</strong> property is responsible for <strong>extrapyramidal symptoms</strong>. The dystonic reaction is one of the extrapyramidal symptoms. Features include spasms of muscles of the tongue, face, neck, and back. It can be treated with <strong>diphenhydramine </strong>or<strong> benztropine</strong>.</p>\n<p>Other extrapyramidal symptoms include<strong> parkinsonian-like symptoms</strong> that may occur several weeks after initiation of therapy. It responds to treatment with anticholinergic or antihistaminic drugs and reverses on discontinuation of metoclopramide. <strong>Tardive dyskinesia</strong> can develop in patients treated for a <strong>prolonged period</strong> with metoclopramide.</p>\n<p><strong>Other options:</strong></p>\n<p>Option A: <strong>Phenelzine</strong> is a <strong>monoamine oxidase (MAO) inhibitor</strong>. It inhibits MAO<sub>A</sub> and MAO<sub>B</sub> to prevent the breakdown of norepinephrine, dopamine, and serotonin. It is used in the treatment of major depression. The major adverse effects include weight gain, sexual dysfunction, and <strong>hypertensive crisis</strong> if taken along with tyramine-containing foods/ beverages.</p>\n<p>Option C: <strong>Chlorpromazine</strong> is a <strong>dopamine receptor antagonist</strong> and is classified under typical antipsychotics. They are noted to improve the positive symptoms of schizophrenia and acute mania. The major adverse effects are extrapyramidal side effects, sedation, weight gain, hypotension, metabolic adverse effects, and photosensitivity.</p>\n<p>Option D: <strong>Prochlorperazine</strong> is a <strong>dopamine receptor antagonist</strong> which is used as an anti-emetic. It is mainly used in motion sickness. The main adverse events are extrapyramidal symptoms including dystonia, cardiac effects, and hypotension.</p><hr><h3>Related Pearl: Extrapyramidal side effects of antipsychotic drugs</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Adverse reactions</strong></span></div>\n</td>\n<td>\n<div><span><strong>Time of onset</strong></span></div>\n</td>\n<td>\n<div><span><strong>Features</strong></span></div>\n</td>\n<td>\n<div><span><strong>Treatment</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Acute dystonia</strong></span></div>\n</td>\n<td>\n<div class=\"p1\"><span>1 to 5 days</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Spasm of muscles of tongue, face, neck, back</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Diphenhydramine or benztropine</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Akathisia</strong></span></div>\n</td>\n<td>\n<div class=\"p1\"><span>5 to 60 days</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Restlessness</span></div>\n</td>\n<td>\n<div><span><strong>Propranolol</strong>,<strong>&nbsp;</strong>lorazepam, diphenhydramine, benztropine</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Parkinsonism</strong></span></div>\n</td>\n<td>\n<div class=\"p1\"><span>5 to 30 days</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Bradykinesia, rigidity, tremors</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Dose reduction, change medication, antiparkinsonian agents</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Tardive dyskinesia</strong></span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Months to years</span></div>\n</td>\n<td>\n<div class=\"p1\">\n<div class=\"p1\"><span>Orofacial dyskinesia (may be reversible with early recognition and drug discontinuation)</span></div>\n</div>\n</td>\n<td>\n<div class=\"p1\"><span>VMAT-2 inhibitors <strong>valbenazine</strong> and <strong>deutetrabenazine</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Neuroleptic malignant syndrome</strong></span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Weeks to months</span></div>\n</td>\n<td>\n<div class=\"p1\"><span>Extreme rigidity, fever, unstable blood pressure</span></div>\n</td>\n<td>\n<div class=\"p1\"><span><strong>Dantrolene</strong></span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2225",
      "difficulty": "medium"
    },
    {
      "text": "A 48-year-old man is diagnosed with diabetes mellitus type 2. He says that he does not prefer injections. He had 1 episode of pancreatitis 3 years back and has a history of colon cancer in his family. He also has been diagnosed with heart failure and has been taking medications. Which of the following drugs can be given to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Pioglitazone"
        },
        {
          "id": 2,
          "text": "Exenatide"
        },
        {
          "id": 3,
          "text": "Glimepiride"
        },
        {
          "id": 4,
          "text": "Teduglutide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Glimepiride </strong>can be given to this patient. It belongs to the class called sulfonylureas.</p>\n<p>Sulfonylureas act by&nbsp;<strong>closing the ATP-sensitive K channels</strong>&nbsp;in the <strong>beta-cells</strong> of the pancreas. This closure causes cell membrane depolarization and the release of insulin. They are readily absorbed from the gastrointestinal tract and therefore can be given orally. Important sulfonylureas are <strong>glimepiride, glipizide, glyburide</strong>, etc.</p>\n<p>Important adverse effects are <strong>hypoglycemia,&nbsp;</strong>vomiting, cholestatic jaundice, agranulocytosis, and aplastic and hemolytic anemias. They can also cause a disulfiram-like reaction. They should be used with caution in pregnancy, lactation, and&nbsp;significant hepatic or renal insufficiency (for the older forms).</p>\n<p>Other options</p>\n<p>Option A- <strong>Pioglitazone</strong> belongs to a class of <strong>thiazolidinediones</strong>. It activates the peroxisome proliferator-activated receptor &gamma;&nbsp;<strong>(PPAR&gamma;)</strong> and increases insulin sensitivity. Apart from weight gain, it also causes edema and fluid retention. It increases the plasma volume and is therefore unsuitable for heart failure patients.</p>\n<p>Option B- <strong>Exenatide</strong> is a glucagon-like peptide-1 (<strong>GLP-1</strong>) receptor agonist. It stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, reduces food intake, and normalizes fasting and postprandial insulin secretion. It is given <strong>subcutaneously.</strong>&nbsp;It can also cause pancreatitis, and therefore is not used in patients with a history or risk of developing <strong>pancreatitis.</strong></p>\n<p>Option D- <strong>Teduglutide</strong> is a glucagon-like peptide-2 (<strong>GLP-2</strong>)&nbsp;analog. It enhances the growth of intestinal mucosa. It is used in the treatment of <strong>short bowel syndrome</strong> and not diabetes mellitus. It is administered parenterally and discontinued in patients with active gastrointestinal malignancy.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9175",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following anti-glaucoma agents has no effect on aqueous outflow?",
      "choices": [
        {
          "id": 1,
          "text": "Netarsudil"
        },
        {
          "id": 2,
          "text": "Timolol"
        },
        {
          "id": 3,
          "text": "Brimonidine"
        },
        {
          "id": 4,
          "text": "Latanoprost"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Timolol</strong> is a <strong>non-selective beta-blocker. </strong>Beta-blockers reduce intra-ocular pressure primarily by<strong> reducing aqueous humor</strong> production. Another hypothesis states that by reducing ocular blood flow, there may be a decrease in ultrafiltration responsible for aqueous production. </p>\n<p><strong>Netarsudil</strong> is a rho-kinase inhibitor that acts by increasing trabecular outflow.</p>\n<p><strong>Brimonidine</strong> is an alpha-agonist that has a small effect on increasing both uveoscleral and trabecular outflow. </p>\n<p><strong>Latanoprost</strong> is a prostaglandin PGF2-alpha analog that primarily acts by releasing matrix metalloproteinases, thereby increasing trabecular and uveoscleral outflow.</p><hr><h3>Related Pearl: Antiglaucoma drugs: Mechanism of lowering intraocular pressure (IOP) at a glance</h3><p><strong>Drugs that increase trabecular outflow</strong></p>\n<ul>\n<li>Miotics (e.g., pilocarpine)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Bimatoprost</li>\n<li>Rho-kinase inhibitor (Netarsudil)</li>\n</ul>\n<p><strong>Drugs that increase uveoscleral outflow</strong></p>\n<ul>\n<li>Prostaglandins (latanoprost)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Brimonidine</li>\n<li>Apraclonidine</li>\n</ul>\n<p><strong>Drugs that decrease aqueous production</strong></p>\n<ul>\n<li>Carbonic anhydrase inhibitors (e.g., acetazolamide, dorzolamide)</li>\n<li>Alpha receptor stimulators in ciliary process (e.g., epinephrine, dipivefrine, clonidine, brimonidine, apraclonidine)</li>\n<li>Beta-blockers</li>\n</ul>\n<p><strong>Hyperosmotic agents</strong> - (e.g., glycerol, mannitol, urea)</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/52d74961d2524b3bb5c22c2677259778x1280x1532.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4642",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is a prostacyclin analog that can be added to the treatment regimen of a patient with pulmonary artery hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Sildenafil"
        },
        {
          "id": 2,
          "text": "Misoprostol"
        },
        {
          "id": 3,
          "text": "Dinoprost"
        },
        {
          "id": 4,
          "text": "Iloprost"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Iloprost </strong>is a<strong> prostacyclin analog </strong>indicated in the management of <strong>pulmonary artery hypertension</strong>. It falls under the category of&nbsp;IP receptor (prostacyclin receptor) agonists.</p>\n<p class=\"p1\">Other drugs falling under the category of <strong>IP receptor agonists</strong> are:</p>\n<ul>\n<li class=\"p1\">\n<p class=\"p1\">Epoprostenol</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Treprostinil</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Iloprost</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Selexipag</p>\n</li>\n</ul>\n<p>Option A: Sildenafil is a PDE-5 inhibitor.&nbsp;</p>\n<p class=\"p1\">Option B: Misoprostol is a synthetic PGE1 analog.&nbsp;</p>\n<p>Option C: Dinoprost is a natural PGF2-alpha preparation. It should&nbsp;not be confused with dinoprostone which is a synthetic analogue of PGE2.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8748",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old female has complaints of marked dryness in her mouth associated with difficulty in swallowing. Schirmer's test is suggestive of severe dry eye. An immunoassay shows the presence of anti-Ro/SS-A and anti-La/SS-B antibodies. Which of the following drugs would be most helpful, with fewer side effects, in this scenario?",
      "choices": [
        {
          "id": 1,
          "text": "Bethanechol"
        },
        {
          "id": 2,
          "text": "Varenicline"
        },
        {
          "id": 3,
          "text": "Cevimeline"
        },
        {
          "id": 4,
          "text": "Pilocarpine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><span data-preserver-spaces=\"true\">The clinical symptoms together with the presence of anti-Ro/SS-A and anti-La/SS-B antibodies are suggestive of&nbsp;</span><strong><span data-preserver-spaces=\"true\">Sjogren syndrome. Cevimeline</span></strong><span data-preserver-spaces=\"true\">&nbsp;would be the best drug for treatment in this case. </span></p>\n<p><span data-preserver-spaces=\"true\">Cevimeline is a&nbsp;</span><strong><span data-preserver-spaces=\"true\">muscarinic agonist</span></strong><span data-preserver-spaces=\"true\">&nbsp;with an affinity for both&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1</span></strong><span data-preserver-spaces=\"true\">&nbsp;and</span><strong><span data-preserver-spaces=\"true\">&nbsp;M3&nbsp;</span></strong><span data-preserver-spaces=\"true\">receptors on the lacrimal and salivary glands.&nbsp;</span><span data-preserver-spaces=\"true\">While&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1 activation </span></strong>results in <strong><span data-preserver-spaces=\"true\">increased secretion</span></strong><span data-preserver-spaces=\"true\">,&nbsp;</span><strong><span data-preserver-spaces=\"true\">M3 activation </span></strong>results in<strong><span data-preserver-spaces=\"true\"> smooth muscle contraction</span></strong><span data-preserver-spaces=\"true\">, and expulsion of the secretions.</span></p>\n<p><span data-preserver-spaces=\"true\">Cevimeline enhances lacrimal secretions in&nbsp;</span><strong><span data-preserver-spaces=\"true\">Sjögren&rsquo;s syndrome.</span></strong></p>\n<p><span data-preserver-spaces=\"true\">Cevimeline has a long-lasting sialogogic action.&nbsp;The usual dose is&nbsp;<strong>30 mg three times daily.&nbsp;</strong>It has fewer side effects than non-selective pilocarpine.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4971",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old man presents with complaints of palpitations. Examination reveals he is hemodynamically stable. The consultant asks you to administer lidocaine as his ECG was suggestive of monomorphic ventricular tachycardia. The drug you have administered belongs to which class of anti-arrhythmic drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Class IA"
        },
        {
          "id": 2,
          "text": "Class IIA"
        },
        {
          "id": 3,
          "text": "Class IB"
        },
        {
          "id": 4,
          "text": "Class IIB"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Lidocaine</strong> belongs to <strong>class IB of anti-arrhythmic drugs</strong>. It is used for acute treatment of ventricular tachycardia and ventricular fibrillation.</p>\n<p><strong>Lidocaine</strong> is a class, <strong>IB</strong> anti-arrhythmic agent. It <strong>blocks Na+</strong> channels mostly in the <strong>closed/inactivated state</strong>. It is not used in atrial arrhythmias because the atrial action potential is so short that the Na+ channels are in a closed/ inactivated state for only a brief amount of time.</p>\n<p>Lidocaine is used in the <strong>acute treatment of ventricular tachycardia and ventricular fibrillation.</strong></p>\n<div class=\"O0\">Drugs mostly used for supraventricular arrhythmia :</div>\n<ul>\n<li class=\"O1\">Adenosine</li>\n<li class=\"O1\">Verapamil</li>\n<li class=\"O1\">Diltiazem</li>\n<li class=\"O1\">Digoxin</li>\n</ul>\n<div class=\"O1\">Ventricular arrhythmia :</div>\n<ul>\n<li class=\"O1\">Lidocaine </li>\n<li class=\"O1\">Mexiletine</li>\n</ul>\n<div class=\"O1\">Both :</div>\n<ul>\n<li class=\"O1\">Amiodarone</li>\n<li class=\"O1\">Beta-blockers</li>\n<li class=\"O1\">Class 1a / 1c antiarrhythmics</li>\n</ul><hr><h3>Related Pearl: Anti-arrhythmic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span>&nbsp;</span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property&nbsp;</span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property&nbsp;</span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>&beta;- blockers</span></td>\n<td><span>-&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers&nbsp;</span></td>\n<td><span>Prolonged&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2267",
      "difficulty": "easy"
    },
    {
      "text": "A 52-year-old male complained of occasional acute attacks of intense panic and anxiety with marked physical symptoms, including shortness of breath, palpitations, sweating, tremors, and fear of impending doom. Which of the following drugs can be used to treat the given condition?",
      "choices": [
        {
          "id": 1,
          "text": "Propranolol"
        },
        {
          "id": 2,
          "text": "Flumazenil"
        },
        {
          "id": 3,
          "text": "Clonazepam"
        },
        {
          "id": 4,
          "text": "Buspirone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical features described are diagnostic of panic disorder, which are commonly treated with benzodiazepines such as <strong>Clonazepam.</strong></p>\n<p><strong>Benzodiazepines</strong> act by binding to specific <strong>GABA-A</strong> receptor subunits at the <strong>cen</strong>t<strong>ral</strong> nervous system (CNS) neuronal synapses. This facilitates the GABA-mediated chloride ion channel opening frequency.</p>\n<p><strong>Therapeutic uses</strong> of benzodiazepines:</p>\n<ul>\n<li>To treat acute <strong>anxiety</strong> states, <strong>panic attacks,</strong> and <strong>generalized anxiety disorder.</strong></li>\n<li>Treatment of <strong>insomnia</strong> and other sleep disorders.</li>\n<li>Also used for relaxation of the skeletal muscle, as an <strong>adjunct</strong> in anaesthesia, and <strong>seizure</strong> disorders.</li>\n</ul>\n<p><strong>Overdose of benzodiazepines</strong> may cause dose-dependent depressive effects, which include: sedation, amnesia, hypnosis, anaesthesia, coma, and respiratory depression.</p>\n<p><strong>Other options:</strong></p>\n<ul>\n<li><strong>Propranolol </strong>may be used for treating performance anxiety, such as stage fright or fear of public speaking. However, propranolol is not primarily indicated for the treatment of the panic disorder. However, they are occasionally used due to side-effects such as hypotension.</li>\n<li><strong>Flumazenil</strong> is a benzodiazepine receptor antagonist. It is indicated in the treatment of benzodiazepine overdose, or for reversal of the sedative effects caused by benzodiazepines.</li>\n<li><strong>Buspirone</strong> is a 5-HT receptor agonist. It is used in the treatment of generalised anxiety states (not for other anxiety disorders or panic attacks).</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6766",
      "difficulty": "medium"
    },
    {
      "text": "A 32-year-old woman presents to the OPD with complaints of curdy white vaginal discharge, dysuria, and intense itching. Per speculum examination of the vagina is done as shown below. A wet smear with 10% KOH solution shows budding yeast cells. The clinician prescribes an oral medication. What is the likely mechanism of action of the given medication?",
      "choices": [
        {
          "id": 1,
          "text": "Forms pores in the fungal cell wall"
        },
        {
          "id": 2,
          "text": "Inhibits microtubule assembly"
        },
        {
          "id": 3,
          "text": "Inhibits fungal squalene epoxidation"
        },
        {
          "id": 4,
          "text": "Inhibits ergosterol biosynthesis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The clinical symptoms of curdy white vaginal discharge and the KOH smear showing budding yeast cells are suggestive of <strong>vulvovaginal candidiasis</strong>. The oral medication given in this condition is <strong>fluconazole </strong>which acts by<strong> inhibiting ergosterol synthesis.</strong></p>\n<p>Azole group of antifungal are grouped into two types :</p>\n<ul>\n<li><strong>Imidazole</strong>- clotrimazole, ketoconazole, luliconazole</li>\n<li><strong>Triazole</strong>- Itraconazole, <strong>fluconazole</strong>, voriconazole, posaconazole, and isavuconazole</li>\n</ul>\n<p>The <strong>azole </strong>group <strong>inhibits</strong> the fungal cytochrome P450 enzyme called <strong>14-α-sterol demethylase</strong> and results in an impaired conversion of lanosterol to ergosterol. This results in the depletion of membrane ergosterol.</p>\n<p><strong>Therapeutic uses</strong> of fluconazole-</p>\n<ul>\n<li><strong>Oropharyngeal candidiasis</strong> can be treated with fluconazole by taking 100–200 mg a day for 7–14 days. Uncomplicated <strong>vaginal candidiasis</strong> can be effectively treated with a single 150 mg dose. Treatment of candidemia in nonimmunosuppressed patients involves a loading dosage of 800 mg, followed by 400 mg daily.</li>\n<li>For the first eight weeks of the consolidation phase of the therapy of <strong>cryptococcal meningitis</strong> in individuals with AIDS, fluconazole is administered.</li>\n<li>Due to its excellent CSF penetration and significantly lower morbidity than intrathecal amphotericin B, fluconazole is the medication of choice for treating <strong>coccidioidal meningitis</strong>. Fluconazole is similar to itraconazole in treating various types of coccidioidomycosis.</li>\n</ul>\n<p>Other options</p>\n<p>Option A- <strong>Amphotericin B</strong> acts by <strong>forming pores </strong>in the fungal <strong>cell membrane.</strong> It has also been found that it forms aggregates that sequester ergosterol from lipid bilayers, leading to fungal cell death. It is indicated in invasive mucormycosis, fungal endophthalmitis following pars plana vitrectomy, and induction therapy in cryptococcal meningitis. </p>\n<p>Option B- <strong>Griseofulvin</strong> acts by <strong>inhibiting microtubule assembly</strong>, disrupting the fungal cell division. It is the drug of choice for tinea capitis in children. It is also effective in treating ringworm of glabrous skin, tinea cruris, tinea corprosis, tinea pedis, and tinea of the hands and beard. </p>\n<p>Option C- <strong>Terbinafine</strong> acts by <strong>inhibiting</strong> <strong>epoxidation of fungal squalene</strong> that<strong> </strong>reduces ergosterol biosynthesis. It is helpful for treating nail onychomycosis in adults and tinea capitis.</p><hr><h3>Related Pearl: Mechanism of action of Antifungal drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e48d5ad74a9b48c6baa33c90914e13cbx1280x2560.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Vaginal infections</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Bacterial vaginosis</strong></td>\n<td><strong>Trichomonas vaginitis</strong></td>\n<td>\n<p><strong>Candidal vaginitis</strong></p>\n</td>\n</tr>\n<tr>\n<td>Causative organism&nbsp;</td>\n<td>Altered vaginal flora- increased concentration of <strong><em>Gardnerella vaginalis</em></strong></td>\n<td><strong><em>Trichomonas vaginalis</em></strong></td>\n<td><strong><em>Candida albicans</em></strong></td>\n</tr>\n<tr>\n<td>Aetiology</td>\n<td>Increased vaginal pH</td>\n<td>Sexually transmitted</td>\n<td>Decreased immunity</td>\n</tr>\n<tr>\n<td>Sexual transmission</td>\n<td>No</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Discharge</td>\n<td>Fishy, thin, yellow</td>\n<td>Frothy, green</td>\n<td>Curdy, white</td>\n</tr>\n<tr>\n<td>Symptoms</td>\n<td>Fishy odour, no itching</td>\n<td>Itching and burning</td>\n<td>Itching, burning</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>&gt;4.5</td>\n<td>&gt;4.5</td>\n<td>&lt;4.5</td>\n</tr>\n<tr>\n<td>Speculum</td>\n<td>No vaginal epithelium inflammation</td>\n<td>Strawberry cervix</td>\n<td>Inflamed-epithelium</td>\n</tr>\n<tr>\n<td>KOH</td>\n<td>Positive Whiff test</td>\n<td>The whiff test can be positive.</td>\n<td>Pseudohyphae seen.</td>\n</tr>\n<tr>\n<td>Wet mount</td>\n<td>Clue cells. No WBCs seen</td>\n<td>Motile trichomaonads, WBCs seen</td>\n<td>WBCs seen</td>\n</tr>\n<tr>\n<td>Treatment</td>\n<td>Metronidazole or Clindamycin</td>\n<td>Metronidazole, treat&nbsp;partner also</td>\n<td>Oral or vaginal azole, no need to treat partner.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e3e18e474cbb42dfb5c02f37d96d3b78.jpg"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8361",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is a soluble guanylate cyclase stimulator that can be used in chronic heart failure with reduced ejection fraction?",
      "choices": [
        {
          "id": 1,
          "text": "Riociguat"
        },
        {
          "id": 2,
          "text": "Vericiguat"
        },
        {
          "id": 3,
          "text": "Omapatrilat"
        },
        {
          "id": 4,
          "text": "Treprostinil"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div><strong>Vericiguat </strong>is an oral <strong>soluble guanylate cyclase stimulator</strong> that can be used in the treatment of <strong>chronic heart failure with reduced ejection fraction.</strong></div>\n<div> </div>\n<div>By stimulating guanylate cyclase, it enhances the production of cGMP which leads to smooth muscle relaxation and vasodilatation. It also enhances the sensitivity of soluble guanylate cyclase to endogenous NO which further contributes to increased cGMP. </div>\n<div> </div>\n<div>It <strong>reduces the risk of cardiovascular death</strong> following hospitalization for heart failure in symptomatic chronic heart failure and ejection fraction &lt;45%.</div>\n<div> </div>\n<div>Other options:</div>\n<div> </div>\n<div>Option A: <strong>Riociguat</strong> is also a <strong>soluble guanylate cyclase stimulator</strong> but it is used in <strong>pulmonary artery hypertension</strong> and not in heart failure.</div>\n<div> </div>\n<div>Option C: <strong>Omapatrilat</strong> is a <strong>neprilysin and ACE inhibitor</strong> developed for heart failure that is not used due to the side effect of increased levels of bradykinin. </div>\n<div> </div>\n<div>Option D: <strong>Treprostinil</strong> is a prostacyclin analog that acts as a <strong>vasodilator</strong> used in the treatment of <strong>pulmonary arterial hypertension. </strong></div><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8024",
      "difficulty": "hard"
    },
    {
      "text": "As a researcher employed in a pharmaceutical company, you are involved in a clinical trial. A monoclonal antibody for the treatment of renal cell carcinoma (RCC) is entering phase III of the clinical trial. Which of these statements correctly describes this phase?",
      "choices": [
        {
          "id": 1,
          "text": "250 healthy volunteers from the general population, randomized and blinded"
        },
        {
          "id": 2,
          "text": "2946 patients with RCC, randomized and double-blinded"
        },
        {
          "id": 3,
          "text": "96 healthy volunteers in an open-label study, to study adverse effects"
        },
        {
          "id": 4,
          "text": "5548 patients with RCC in an open-label observational study"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Phase III trials</strong> are usually done on <strong>500&ndash;3000 patients</strong> with the disease, and these are <strong>randomized double-blinded studies</strong>.</p>\n<p><strong>Phase III trials </strong>are usually considered<strong> pivotal trials </strong>that are necessary for the <strong>approval </strong>of the majority of drugs.<strong>&nbsp;</strong>They<strong>&nbsp;</strong>are<strong>&nbsp;</strong>also called a multisite trial, which is done for 3&ndash;5 years. This phase <strong>confirms</strong> the <strong>efficacy</strong> of the drug. It is also done to study the <strong>long-term</strong> or<strong> rare side effects</strong> of this drug.&nbsp;</p>\n<p>When the initial phase III trials are complete, the sponsor (usually a pharmaceutical company) applies to the FDA for approval to market the drug. This application is called either a <strong>new drug application </strong>(NDA) or<strong> a biologics license application </strong>(BLA).</p>\n<p>Note: In some drugs related to rare diseases or oncology, phase II studies are considered pivotal, and the drug may be approved on the basis of phase II studies.</p>\n<p><strong>Other phases of clinical trials:</strong></p>\n<p><strong>Preclinical trials </strong>are performed on animals and they are regulated by guidelines prescribed by&nbsp;the committee for the purpose of the control and supervision of experiments on animals (<strong>CPCSEA</strong>) in India. Standards for the conduct of clinical trials involving Indian subjects are laid down in good clinical practice (GCP).</p>\n<p><strong>Phase I clinical trials</strong> are performed on <strong>healthy volunteers</strong> in an open-label study to determine the safety, tolerability, and <strong>pharmacokinetic</strong> properties of the drug.</p>\n<p><strong>Phase II clinical trials </strong>are conducted to evaluate the appropriate <strong>dose range</strong> of the drug. It is evaluated on a small group of patients (50-500) with the target disease. Most of the new drugs will be administered for the first time in <strong>patients with </strong>the <strong>target disease</strong>.</p>\n<p>The study is designed to obtain <strong>proof of concept </strong>(potential of the drug to treat the disease) and <strong>dose-ranging study </strong>(provides input for choosing the most appropriate dose for phase III studies).</p>\n<p><strong>Phase IV clinical</strong><strong> trials</strong> are conducted after the<strong> drug is marketed</strong> and&nbsp;approved by regulatory authorities. It includes <strong>post-marketing surveillance</strong> and other studies that complement the earlier findings on the drug.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multi-site trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Post-marketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10 – 100 </p>\n</td>\n<td>\n<p>50 - 500 </p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial; may be blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial; may be blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology </strong>and<strong> safety</strong>: To determine safety, tolerability and pharmacokinetic parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration </strong>and<strong> dose-ranging</strong>: To determine efficacy and dose-ranging</p>\n</td>\n<td>\n<p> </p>\n<p><strong>Therapeutic confirmation </strong>and <strong>comparison</strong>: Indications are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions is done. </p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance</strong>: To monitor drug interactions, compliance and long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from months to 1 year</p>\n</td>\n<td>\n<p>1–2 years</p>\n</td>\n<td>\n<p>3–5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Randomized Controlled Trials</h3><p><strong>Randomized controlled trials</strong> are a type of <strong>experimental studies</strong>.</p>\n<p><strong>Types</strong></p>\n<ul>\n<li>Clinical trials</li>\n<li>Preventive trials</li>\n<li>Risk factor trials</li>\n<li>Cessation experiments</li>\n<li>Trial of etiological agents</li>\n<li>Evaluation of health services</li>\n</ul>\n<p><strong>General Design of an RCT</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b18b067a5846405b95d6bb11b2e1546fx1280x1482.JPEG\" alt=\"Pearl Image\"><p><strong>Steps of an RCT</strong></p>\n<ul>\n<li>Drawing up a <strong>protocol</strong></li>\n<li>Selecting <strong>reference and experimental</strong> population</li>\n<li><strong>Randomization</strong></li>\n<li>Manipulation or <strong>intervention</strong></li>\n<li><strong>Follow-up</strong></li>\n<li><strong>Assessment</strong> of outcome.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8138",
      "difficulty": "medium"
    },
    {
      "text": "A 58-year-old man was treated with an intravenous diuretic for heart failure. Now he presents with  tinnitus,  vertigo, a sense of fullness in the ears and difficulty in hearing from the right ear. Examination shows Weber’s test localised to the left ear and Rinne’s test shows AC>BC in both ears.  The responsible offending agent acts most likely in which part of the nephron?",
      "choices": [
        {
          "id": 1,
          "text": "Descending limb of the loop of Henle"
        },
        {
          "id": 2,
          "text": "Thick ascending limb of the loop of Henle"
        },
        {
          "id": 3,
          "text": "Proximal convoluted tubule"
        },
        {
          "id": 4,
          "text": "Distal convoluted tubule"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical scenario is suggestive of a drug-induced sensorineural type of hearing loss, and <strong>furosemide</strong> is likely to be associated with these side effects (<strong>ototoxicity</strong>). This is due to the adverse effect of IV furosemide used during his heart failure treatment. Furosemide <strong>acts on the thick ascending limb of the loop of Henle</strong>.</p>\n<p>Interpretation of the given audiogram:</p>\n<ul>\n<li>Red indicates right ear</li>\n<li>O indicates AC and threshold is &gt;15 dB. Hence <strong>AC is abnormal</strong></li>\n<li>&lt; indicates BC and threshold is &gt;25 dB. Hence <strong>BC is abnormal</strong></li>\n<li>Both AC and BC are abnormal. It <strong>indicates sensorineural hearing loss</strong></li>\n<li>There is <strong>no Air-Bone gap</strong></li>\n<li>Hence it is <strong>right side sensorineural hearing loss</strong></li>\n</ul>\n<p>Since Weber is lateralised towards left, it indicates <strong>left sided conductive deafness</strong> or <strong>right sided sensorineural deafness</strong>. Since Rinne is positive on both ears, <strong>conductive deafness is ruled out</strong>. Therefore, it is <strong>Right sided sensorineural hearing loss.</strong></p>\n<p><strong>Other options:</strong></p>\n<p><strong>Carbonic anhydrase</strong> acts on the <strong>PCT</strong>. It is used for glaucoma, pseudotumor cerebri, metabolic alkalosis and cystine stone prevention.Due to their structural homology to the sulfonamides, they may cause bone marrow depression, skin toxicity, and allergic reactions.</p>\n<p><strong>Thiazides</strong> act on the <strong>DCT</strong>. It is used for treatment of hypertension and chronic edema. Their adverse effects are as follows</p>\n<ul>\n<li>Hypotension</li>\n<li>Hyponatremia</li>\n<li>Hypokalemia</li>\n<li>Hypomagnesemia</li>\n<li>Hypochloremia</li>\n<li>Hyperuricemia</li>\n<li>Hypercalcemia</li>\n<li>Decrease glucose tolerance</li>\n<li>May increase the lipid levels</li>\n</ul>\n<p><strong>ADH receptor antagonists</strong> like <strong>Tolvaptan</strong> act in <strong>medullary CT.</strong> Used for treating hyponatremia. They can cause hypokalemia, dehydration, liver damage (eps contraindicated in people with previous liver disease) as side effects.</p>\n<p>Other common <strong>ototoxic drugs</strong> are:</p>\n<ol>\n<li>Antibiotics like Aminoglycosides ( gentamicin &gt; tobramycin &gt; amikacin &gt; neomycin), erythromycin, tetracyclines.</li>\n<li>Chemotherapeutic agents like Cisplatin, Bleomycin and Nitrogen mustard.</li>\n<li>High dose aspirin, acetaminophen and NSAID’s</li>\n<li>Antimalarials like quinine and quinidine</li>\n<li>Phosphodiesterase 5 inhibitors like Sildenafil</li>\n</ol><hr><h3>Related Pearl: Tuning fork tests</h3><table>\n<tbody>\n<tr>\n<td><strong>Tests</strong></td>\n<td><strong>Normal</strong></td>\n<td>\n<div><strong>Conductive</strong><strong>&nbsp;</strong></div>\n<div><strong>loss</strong></div>\n</td>\n<td>\n<div><strong>Sensorineural</strong></div>\n<div><strong>loss</strong></div>\n</td>\n</tr>\n<tr>\n<td><strong>Rinne</strong></td>\n<td>AC &gt; BC (Rinne +)</td>\n<td>BC &gt; AC (Rinne -)</td>\n<td>AC &gt; BC (Rinne +)</td>\n</tr>\n<tr>\n<td><strong>Weber</strong></td>\n<td>Center</td>\n<td>Lateralized to the affected ear</td>\n<td>Lateralized to the normal ear</td>\n</tr>\n<tr>\n<td><strong>Absolute bone conduction</strong></td>\n<td>Normal</td>\n<td>Normal</td>\n<td>Reduced</td>\n</tr>\n<tr>\n<td><strong>Schwabach</strong></td>\n<td>Normal</td>\n<td>Lengthened</td>\n<td>Shortened</td>\n</tr>\n<tr>\n<td><strong>Bing</strong></td>\n<td>Positive</td>\n<td>Negative</td>\n<td>Positive</td>\n</tr>\n<tr>\n<td><strong>Gelle</strong></td>\n<td>Positive</td>\n<td>Negative (ossicular lesions)</td>\n<td>Positive</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>AC- Air conduction; BC- Bone conduction.</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div><hr><h3>Related Pearl: Site and mechanism of action of diuretics</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Diuretics&nbsp;</strong></span></td>\n<td><span><strong>Site of action&nbsp;&nbsp;</strong></span></td>\n<td>\n<p><span><strong>Enzyme/receptor</strong><strong>/transporter inhibited&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Carbonic anhydrase inhibitors&nbsp;&nbsp;</strong></span></td>\n<td><span>Proximal tubule&nbsp;&nbsp;</span></td>\n<td><span>Carbonic anhydrase&nbsp;&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>Loop diuretics&nbsp;</strong></span></td>\n<td><span>Thick ascending loop of Henle&nbsp;</span></td>\n<td><span>Na<sup>+</sup>- K<sup>+</sup>- 2Cl<sup>-</sup>&nbsp;symporter</span></td>\n</tr>\n<tr>\n<td><span><strong>Thiazides</strong></span></td>\n<td><span>Distal convoluted tubule&nbsp;</span></td>\n<td><span>Na<sup>+</sup>- Cl<sup>-</sup> symporter</span></td>\n</tr>\n<tr>\n<td><span><strong>Epithelial sodium channel inhibitors&nbsp;</strong></span></td>\n<td><span>Late distal tubule and collecting ducts&nbsp;&nbsp;</span></td>\n<td><span>ENaC&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>Aldosterone antagonists&nbsp;</strong></span></td>\n<td><span>Late distal tubule and collecting ducts&nbsp;</span></td>\n<td><span>Mineralocorticoid receptors (indirectly ENaC)&nbsp;</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1eebed7de1f34fd99539e6c7613f42f0x1280x1306.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f480fd2cb0f44bedbe11cd63e16c01d9.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7635",
      "difficulty": "medium"
    },
    {
      "text": "Sugammadex is a reversal agent for:",
      "choices": [
        {
          "id": 1,
          "text": "Neostigmine"
        },
        {
          "id": 2,
          "text": "Atropine"
        },
        {
          "id": 3,
          "text": "Rocuronium"
        },
        {
          "id": 4,
          "text": "Glycopyrrolate"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Sugammadex</strong> is a<strong> reversal agent </strong>for <strong>rocuronium</strong> and <strong>vecuronium.</strong></p>\n<p>Sugammadex binds to plasma rocuronium and thus decreases the plasma concentration of rocuronium. This forms a concentration gradient of rocuronium due to which it moves from the neuromuscular junction back into the circulation where it quickly bound by free sugammadex. It is not recommended to be used in patients who have severe renal impairment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8214",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is gametocidal to all the species causing malaria?",
      "choices": [
        {
          "id": 1,
          "text": "Primaquine"
        },
        {
          "id": 2,
          "text": "Chloroquine"
        },
        {
          "id": 3,
          "text": "Quinine"
        },
        {
          "id": 4,
          "text": "None"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Primaquine</strong> is <strong>gametocidal</strong> <strong>to all species</strong> causing malaria. It inhibits transmission of malaria.</p>\n<p>The drugs with clinically important gametocidal activity (against all species) are:</p>\n<ul>\n<li>High activity:\n<ul>\n<li>Artemisinins</li>\n<li>Primaquine</li>\n</ul>\n</li>\n<li>Low to moderate activity:\n<ul>\n<li>Chloroquine</li>\n<li>Quinine</li>\n<li>Atovaquone/proguanil</li>\n</ul>\n</li>\n<li>No activity:\n<ul>\n<li>Mefloquine</li>\n<li>Pyrimethamine</li>\n<li>Sulfadoxine</li>\n<li>Tetracycline</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0735275b88fc4d678851ba62673b565ex1280x1621.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7015",
      "difficulty": "easy"
    },
    {
      "text": "A 32-year-old lady with 30 weeks of pregnancy having an obstetric index of G2P1L1 presents to the emergency department with labor pain. A senior resident started the patient on the drug ritodrine to prevent preterm labor. This drug prevents labor by acting as _________",
      "choices": [
        {
          "id": 1,
          "text": "Oxytocin receptor antagonist"
        },
        {
          "id": 2,
          "text": "Beta-2 receptors agonist"
        },
        {
          "id": 3,
          "text": "Calcium channel blocker"
        },
        {
          "id": 4,
          "text": "Prostaglandin antagonist"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div class=\"page\" title=\"Page 830\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ritodrine is a selective <strong>beta-2 receptor agonist</strong>, which is used as a uterine relaxant to prevent preterm labour.</p>\n</div>\n</div>\n</div>\n</div>\n<p>Specific tocolytic agents are:</p>\n<ul>\n<li>Beta 2 agonists \n<ul>\n<li><strong>Ritodrine</strong></li>\n<li>Isoxsuprine</li>\n<li>Terbutaline</li>\n</ul>\n</li>\n<li>Calcium channel blockers: Eg.<strong> Nifedipine</strong></li>\n<li>Magnesium sulfate</li>\n<li><strong>Atosiban (oxytocin receptor antagonist)</strong></li>\n<li>Indomethacin</li>\n</ul><hr><h3>Related Pearl: Tocolytic agents</h3><div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Examples</strong></td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Calcium channel blockers</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Nifedipine <br />Nicardipine<br /> Verapamil</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 606\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Competitive inhibition to calcium ion</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Magnesium sulfate</td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Cyclo-oxygenase inhibitors</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Indomethacin<br />Sulindac</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Beta mimetics</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Terbutaline<br />Ritodrine<br />Isoxsuprine</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Oxytocin Antagonists</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Atosiban</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">Nitric oxide (NO) Donors</div>\n</div>\n</div>\n</td>\n<td>&nbsp;Glyceryl trinitrate (GTN)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2709",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is not true regarding the characteristics of elimination plotted in orange?",
      "choices": [
        {
          "id": 1,
          "text": "It shows saturable elimination"
        },
        {
          "id": 2,
          "text": "Fixed amount of drug is cleared per unit time"
        },
        {
          "id": 3,
          "text": "T1/2 remains constant"
        },
        {
          "id": 4,
          "text": "Exhibited by drugs such as phenytoin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given image, the orange line depicts&nbsp;<strong>zero-order elimination</strong>. The incorrect statement about this type of elimination is that&nbsp;t&frac12; remains constant.&nbsp;In zero-order elimination, the <strong>t&frac12;</strong> is <strong>not constant&nbsp;</strong>and&nbsp;is less at low concentration and more at high concentration.</p>\n<p>Zero-order kinetics denotes that the <strong>rate of elimination</strong> is <strong>constant</strong>&nbsp;regardless of the concentration of the drug. Here a <strong>fixed&nbsp;amount</strong> of drug is cleared per unit time. This is usually seen when the drugs <strong>saturate</strong> their elimination mechanisms. Therefore, as the concentration of the drug increases beyond metabolic saturation, clearance of the drug decreases as depicted by the <strong>orange line.&nbsp;</strong>Drugs such as<strong> phenytoin</strong>, and <strong>aspirin</strong> follow this type of elimination at higher concentrations.&nbsp;</p>\n<p><strong>First-order kinetics</strong> denotes that the <strong>rate of elimination</strong> is <strong>proportional</strong> to the&nbsp;<strong>plasma concentration</strong> of the drug. Here a&nbsp;<strong>constant&nbsp;</strong><strong>fraction</strong> of the drug is eliminated. The drugs following this elimination have a <strong>constant&nbsp;&nbsp;t&frac12;</strong>.&nbsp;As the dosage of the drug increases, the clearance remains constant as the fraction of drug eliminated is constant as depicted by the <strong>black line</strong>. Most drugs follow this type of elimination.&nbsp;</p><hr><h3>Related Pearl: Zero order vs First order kinetics of drugs</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Zero order</strong></p>\n</td>\n<td>\n<p><strong>First order</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Constant <strong>amount</strong> of drug is eliminated per unit time</p>\n</td>\n<td>Constant <strong>fraction</strong> of drug is eliminated per unit time</td>\n</tr>\n<tr>\n<td>\n<p>Rate of elimination is <strong>independent</strong> of plasma concentration</p>\n</td>\n<td>Rate of elimination is <strong>proportional</strong> to the plasma concentration</td>\n</tr>\n<tr>\n<td>\n<p>Clearance is <strong>more at low</strong> concentration and <strong>less at high</strong> concentration</p>\n</td>\n<td>Clearance remains <strong>constant</strong>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Half-life is <strong>less at low</strong> concentration and <strong>more at high</strong> concentration</p>\n</td>\n<td>Half-life remains <strong>constant</strong></td>\n</tr>\n<tr>\n<td>\n<p>Very <strong>few drugs</strong> follow zero-order kinetics, e.g.(<strong>WATT Power</strong>)</p>\n<ul>\n<li><strong>W</strong>arfarin</li>\n<li><strong>A</strong>lcohol,&nbsp;<strong>A</strong>spirin</li>\n<li><strong>T</strong>olbutamide</li>\n<li><strong>T</strong>heophylline&nbsp;</li>\n<li><strong>P</strong>henytoin</li>\n</ul>\n<p>&nbsp;</p>\n</td>\n<td><strong>Most of the drugs</strong> follow first order kinetics&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8bee4685a9ae43ae9d112e3d0790eaffx1280x2445.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f507dd5f24b54315a2176596e260a962.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6783",
      "difficulty": "medium"
    },
    {
      "text": "A drug is instilled into the right eye of the rabbit, and the left eye is used as the control. The findings obtained after some time are shown in the table and image given below.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>Reflex</strong></td>\n<td><strong>Right eye</strong></td>\n<td><strong>Left eye</strong></td>\n</tr>\n<tr>\n<td>Corneal reflex</td>\n<td>Present</td>\n<td>Present</td>\n</tr>\n<tr>\n<td>Light reflex</td>\n<td>Absent</td>\n<td>Present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Which of the following drugs is likely to have been instilled?</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Cocaine"
        },
        {
          "id": 2,
          "text": "Physostigmine"
        },
        {
          "id": 3,
          "text": "Pilocarpine"
        },
        {
          "id": 4,
          "text": "Atropine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>On instillation of the drug, there is <strong>mydriasis</strong> in the eye and <strong>loss of light reflex</strong>. The drug is likely to be <strong>atropine</strong>. It is an anticholinergic agent. It causes mydriasis, cycloplegia, loss of light reflex, and impaired accommodation.</p>\n<p>Autonomic supply of the eye:</p>\n<p>The <strong>radial muscle</strong> of the iris is controlled by <strong>α</strong><span class=\"s1\"><strong>1 adrenergic receptor</strong>. Stimulation of this receptor causes <strong>mydriasis. </strong></span></p>\n<p><span class=\"s1\">The<strong> sphincter muscle </strong>of the iris is controlled by the </span><strong>M<span class=\"s1\">3 and</span> M</strong><span class=\"s1\"><strong>2 cholinergic receptors.</strong> Stimulation of these receptors causes <strong>miosis.</strong></span></p>\n<p><span class=\"s1\"><strong>The ciliary muscle </strong>is supplied by the </span><strong>β</strong><span class=\"s1\"><strong>2</strong> adrenergic receptors as well as </span><strong>M<span class=\"s1\">3 and</span> M</strong><span class=\"s1\"><strong>2</strong> cholinergic receptors. The <strong>β2</strong> receptors cause relaxation of the ciliary muscle, which helps in <strong>far vision,</strong> while <strong>M3 and M2 </strong>receptors cause contraction of the ciliary muscle, which helps in <strong>near vision.</strong></span></p>\n<p><span class=\"s1\"><strong>Lacrimal glands are supplied by the </strong></span>α receptors and M3 and M2 receptors. They increase lacrimal secretion.</p>\n<p>Effects of various drugs on the eye</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Class</strong></td>\n<td><strong>Muscarinic receptor antagonist</strong></td>\n<td><strong>Cholinesterase inhibitors</strong></td>\n<td><strong>Muscarinic receptor agonist</strong></td>\n<td><strong>Adrenergic agonist</strong></td>\n<td><strong>Local anesthetic</strong></td>\n</tr>\n<tr>\n<td>Drugs</td>\n<td><strong>Atropine</strong>, homatropine, Scopalamine, Tropicamide</td>\n<td><strong>Physostigmine</strong>, neostigmine, pyridostigmine, organophosphorus compounds, etc</td>\n<td><strong>Pilocarpine</strong></td>\n<td>Epinephrine</td>\n<td><strong>Cocaine</strong></td>\n</tr>\n<tr>\n<td>Mechanism of action in the eye</td>\n<td><strong>Blocks M3 and M2</strong> receptors</td>\n<td><strong>Stimulates M3 and M2</strong> receptors</td>\n<td><strong>Stimulates M3 and M2</strong> receptors in the eye</td>\n<td><strong>Stimulates α</strong><span class=\"s1\"><strong>1 </strong>receptor  in the eye</span></td>\n<td><strong>Blocks sodium channel</strong> and blocks <strong>norepinephrine transporter</strong></td>\n</tr>\n<tr>\n<td>Effect on iris</td>\n<td>Mydriasis</td>\n<td>Miosis</td>\n<td>Miosis</td>\n<td>Mydriasis</td>\n<td>Mydriasis</td>\n</tr>\n<tr>\n<td>Corneal reflex</td>\n<td>Present</td>\n<td>Present</td>\n<td>Present</td>\n<td>Present</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td>Light reflex</td>\n<td><strong>Absent</strong></td>\n<td>Present</td>\n<td>Present</td>\n<td>Present</td>\n<td>Present</td>\n</tr>\n<tr>\n<td>Lacrimal secretions</td>\n<td>Decreased</td>\n<td>Increased</td>\n<td>Increased</td>\n<td> Increased</td>\n<td>---</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Effect of ANS in the Eye</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td colspan=\"2\"><strong>Adrenergic System</strong></td>\n<td colspan=\"2\"><strong>Cholinergic system</strong></td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Action</strong></td>\n<td><strong>Receptor</strong></td>\n<td><strong>Action</strong></td>\n<td><strong>Receptor</strong></td>\n</tr>\n<tr>\n<td><strong>Iris radial muscle</strong></td>\n<td>Contraction - <strong>Mydriasis</strong></td>\n<td><strong>&alpha;1</strong></td>\n<td>---------</td>\n<td>---------</td>\n</tr>\n<tr>\n<td><strong>Iris circular muscle</strong></td>\n<td>---------</td>\n<td>---------</td>\n<td>Contraction - <strong>Miosis</strong>&nbsp;</td>\n<td><strong>M3</strong></td>\n</tr>\n<tr>\n<td><strong>Ciliary Muscle</strong></td>\n<td>Relaxation &ndash; Far vision</td>\n<td>&beta;2</td>\n<td>Contraction &ndash; Near vision</td>\n<td><strong>M3</strong></td>\n</tr>\n<tr>\n<td><strong>Lacrimal glands</strong></td>\n<td>Secretion +</td>\n<td><strong>&alpha;</strong></td>\n<td>Secretion +</td>\n<td><strong>M3, M2</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/38cc05b0933e4f65a83a650431d5c197.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9178",
      "difficulty": "medium"
    },
    {
      "text": "A 23-year-old pregnant woman presented with features suggestive of thyrotoxicosis. Which of the following is not a treatment option for her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Methimazole"
        },
        {
          "id": 2,
          "text": "Propylthiouracil"
        },
        {
          "id": 3,
          "text": "Radioactive iodine"
        },
        {
          "id": 4,
          "text": "Subtotal thyroidectomy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Radioactive iodine therapy</strong> is<strong> contraindicated</strong> during pregnancy and lactation. Therefore, it is not a treatment option in this patient.</p>\n<p>Thyrotoxicosis in pregnancy:</p>\n<p>The <strong>drug of choice</strong> for the treatment of thyrotoxicosis during the<strong> first trimester </strong>of pregnancy is <strong>propylthiouracil (PTU).</strong></p>\n<p>Methimazole and its prodrug (carbimazole) are usually avoided in the first trimester due to <strong>teratogenic risk.</strong>&nbsp;However, methimazole is used for the remainder of the pregnancy due to the concern for <strong>PTU-associated liver failure.</strong>&nbsp;</p>\n<p><strong>Subtotal thyroidectomy</strong> can be performed during the <strong>mid-trimester.</strong></p>\n<p><strong>Radioactive iodine </strong>crosses the placenta and causes the destruction of the fetal thyroid. Therefore, it&nbsp;is<strong> contraindicated</strong> during pregnancy and lactation.</p>\n<p>Treatment of thyrotoxicosis in pregnancy</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Trimester</strong></td>\n<td><strong>Treatment for thyrotoxicosis</strong></td>\n</tr>\n<tr>\n<td><strong>First trimester</strong></td>\n<td>\n<ul>\n<li>Propylthiouracil</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Second trimester</strong></td>\n<td>\n<ul>\n<li>Methimazole</li>\n<li>Subtotal thyroidectomy</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Third trimester</strong></td>\n<td>\n<ul>\n<li>Methimazole</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Drug of choice for hyperthyroidism/thyrotoxicosis in pregnancy</h3><p>In the 1st trimester: <strong>Propylthiouracil</strong></p>\n<p>In the 2nd and 3rd trimester: <strong>Methimazole</strong></p><hr><h3>Related Pearl: Classification of Anti-Thyroid Drugs</h3><p>&nbsp;Drugs <strong>inhibiting iodide trapping</strong>:</p>\n<ul>\n<li>Thiocyanates</li>\n<li>Perchlorates</li>\n<li>Nitrates</li>\n</ul>\n<p>Drugs <strong>inhibiting hormone synthesis</strong>:</p>\n<ul>\n<li>Propylthiouracil</li>\n<li>Methimazole</li>\n<li>Carbimazole</li>\n</ul>\n<p>Drugs <strong>inhibiting hormone release</strong>:</p>\n<ul>\n<li>Iodine</li>\n<li>Sodium iodide</li>\n<li>Potassium iodide</li>\n<li>Organic iodide</li>\n</ul>\n<p>Drugs <strong>inhibiting peripheral conversion:</strong></p>\n<ul>\n<li>Propylthiouracil</li>\n<li>Amiodarone</li>\n<li>Iodinated contrast dyes (Iopanoic acid)</li>\n<li>Propranolol</li>\n<li>Glucocorticoids</li>\n</ul>\n<p>Drugs that <strong>destroy thyroid tissue</strong>:</p>\n<ul>\n<li>Radioactive iodine</li>\n</ul><img src=\"https://cdn1.dailyrounds.org/uploads/c80ec5fa0ace4523a36894c3898a9be8.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1127",
      "difficulty": "easy"
    },
    {
      "text": "A 40-year-old lady with grade 2 osteoarthritis is on treatment with NSAIDs. She developed heartburn and epigastric pain. An upper GI endoscopy revealed gastritis. Which of the following is the most appropriate advice for her pharmacologically?",
      "choices": [
        {
          "id": 1,
          "text": "Stop NSAIDs and chew capsule pantoprazole for rapid action"
        },
        {
          "id": 2,
          "text": "Switch to etoricoxib instead of NSAIDs and use pantoprazole capsule without chewing"
        },
        {
          "id": 3,
          "text": "Use a combination of antacid and cimetidine for rapid healing"
        },
        {
          "id": 4,
          "text": "Switch to ranitidine along with sucralfate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Among the given options, <strong>switching to etoricoxib</strong> instead of a non-selective COX inhibitor and <strong>using pantoprazole&nbsp;without chewing</strong> would be the most appropriate advice.</p>\n<p><strong>Selective&nbsp;COX2</strong> inhibitors like <strong>etoricoxib</strong> are less likely to cause gastritis than non-selective COX inhibitors like aspirin or ibuprofen.</p>\n<p>Proton pump inhibitors (PPIs) like pantoprazole are generally coated or available in capsule forms. Without this, it gets degraded by the action of gastric acid. Hence uncrushed PPI should be used 1/2 to 1 hour before the meals.</p>\n<p>Other options:</p>\n<p>Option A: NSAIDs may be stopped in view of gastric irritation and switched to another analgesic or surgical option might be undertaken. PPI should not be crushed.</p>\n<p>Option C: A combination of H2 blockers like <strong>cimetidine</strong> and <strong>antacid</strong> should not be administered simultaneously, as the antacids reduce the absorption of all H2 blockers. At least a gap of 2 hours should be maintained.</p>\n<p>Option D:&nbsp;Ranitidine increases&nbsp;the&nbsp;gastric pH&nbsp;(i.e. less acidic) which&nbsp;reduces&nbsp;sucralfate efficacy;&nbsp;hence the <strong>combination is incorrect</strong>.&nbsp;</p>\n<p>Note: Usage of <strong>ranitidine</strong> for any purpose has been banned by the FDA due to a potential carcinogenic agent in a few batches of this drug.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4816",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is commonly used in the treatment of overactive urinary bladder?",
      "choices": [
        {
          "id": 1,
          "text": "Ipratropium"
        },
        {
          "id": 2,
          "text": "Tolterodine"
        },
        {
          "id": 3,
          "text": "Pirenzepine"
        },
        {
          "id": 4,
          "text": "Dicyclomine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Tolterodine </strong>is commonly used in the treatment of the <strong>overactive urinary bladder</strong>. It is a <strong>muscarinic receptor antagonist. </strong></p>\n<p>In an<strong> overactive bladder</strong>, there is an <strong>overactivity </strong>of the <strong>detrusor muscle</strong> due to the up-regulation of <strong>M3 receptors</strong>. Drugs that block these receptors such as tolterodine act by improving bladder capacity, reducing the frequency of bladder contractions, and lowering intravesicular pressure.</p>\n<p>Anticholinergics are muscarinic receptor antagonists and parasympatholytics. The important uses of various anticholinergics are as follows:</p>\n<ul>\n<li>Atropine - for AV block,<strong> organophosphorus poisoning</strong>, and refractive error testing in children (produces cycloplegic mydriasis)</li>\n<li>Scopolamine/ hyoscine (transdermal patch) - for <strong>motion sickness</strong></li>\n<li><strong>Ipratropium</strong> - for chronic obstructive pulmonary disease and rhinorrhea </li>\n<li><strong>Tolterodine</strong> - for childhood <strong>enuresis</strong>, overactive and <strong>neurogenic bladder</strong></li>\n<li><strong>Pirenzepine </strong>(selective M1 receptor antagonist) - for peptic ulcer disease </li>\n<li>Benzhexol/ Trihexyphenidyl - for <strong>Parkinson's</strong> <strong>disease</strong> and drug-induced extrapyramidal symptoms</li>\n<li><strong>Dicyclomine </strong>(direct spasmolytic effect on GI smooth muscle) - for diarrhea-predominant irritable bowel syndrome</li>\n<li>Glycopyrrolate (reduces secretions) - as a <strong>pre-anesthetic</strong> medication</li>\n</ul>\n<p><strong>Adverse effects</strong> of muscarinic antagonists include <strong>dryness of mouth</strong>, <strong>decreased sweating</strong>, thirst, <strong>mydriasis</strong> and blurring of vision, palpitations, and <strong>urinary retention</strong>. CNS effects include restlessness, hallucinations, and delirium.</p><hr><h3>Related Pearl: Muscarinic antagonists indicated for detrusor instability/overactive bladder</h3><table>\n<tbody>\n<tr>\n<td><strong>Mechanism/Feature</strong></td>\n<td><strong>Drug</strong></td>\n</tr>\n<tr>\n<td>Direct smooth muscle relaxant &nbsp;</td>\n<td>\n<p>Flavoxate</p>\n<p>Oxybutynin</p>\n</td>\n</tr>\n<tr>\n<td>Bladder selective &nbsp;</td>\n<td>\n<p>Tolterodine</p>\n<p>Fesoterodine (prodrug)</p>\n</td>\n</tr>\n<tr>\n<td>Only quaternary compound &nbsp;</td>\n<td>Trospium</td>\n</tr>\n<tr>\n<td>M3 selective &nbsp;</td>\n<td>\n<p>Darifenacin</p>\n<p>Solifenacin</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1056",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true about disulfiram?",
      "choices": [
        {
          "id": 1,
          "text": "When used with alcohol, the patients feels drowsy, with chest discomfort and respiratory depression"
        },
        {
          "id": 2,
          "text": "It is an anticraving drug"
        },
        {
          "id": 3,
          "text": "It can be initiated even in minimally motivated person"
        },
        {
          "id": 4,
          "text": "Its action persists up to 2-3 days after stopping the drug"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Disulfiram is used in behavioural modification technique for alcohol de-addiction. The principle of action is <strong>aversive</strong> conditioning.</p>\n<p><strong>Disulfiram</strong>&nbsp;is an&nbsp;<strong>irreversible inhibitor&nbsp;</strong>of both cytosolic and mitochondrial forms of<strong>&nbsp;aldehyde dehydrogenase</strong>. Ethanol consumption during disulfiram therapy can lead to increased concentrations of acetaldehyde. Increased acetaldehyde levels can cause flushing, pulsating headache, throbbing pain in head and neck,&nbsp;nausea, vomiting, rashes, respiratory difficulties, chest pain, autonomic manifestations and other aversive reactions.</p>\n<p>Disulfiram can only be given to <strong>highly motivated</strong> individuals.&nbsp;Disulfiram should not be administered until the person has abstained from alcohol for at least 12 hours. The disulfiram-alcohol reaction may occur as long as<strong> 14 days after the last dose of disulfiram</strong>.</p>\n<p>Disulfiram like reaction with alcohol ingestion is also seen with the following drugs:</p>\n<ul>\n<li>Metronidazole</li>\n<li>Sulfonylureas like chlorpropamide</li>\n<li>Cephalosporins like&nbsp;cefoperazone, cefamandole</li>\n</ul>\n<p>Other modalities of treatment:</p>\n<ul>\n<li><strong>Pharmacotherapy</strong>: Typically 5-10 days, treatment for detoxification: Benzodiazepine and chlordiazepoxide are the drugs of choice.</li>\n<li><strong>Rehabilitation programs:</strong> Typically 28-day programs, learn about relapse prevention and identification of triggers.</li>\n<li><strong>Maintenance phase</strong>: Baclofen, Acamprosate, Naltrexone, Topiramate, SSRI, Ondansetron</li>\n<li><strong>Psychotherapy:</strong> Group therapy such as Alcoholics Anonymous</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6611",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old male patient is undergoing coronary thrombolysis and requires tenecteplase for fibrinolytic therapy. Which of the following conditions is not an absolute contraindication to starting this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Known malignant intracranial neoplasm"
        },
        {
          "id": 2,
          "text": "Ischemic stroke within the last 3 months"
        },
        {
          "id": 3,
          "text": "Suspected aortic dissection"
        },
        {
          "id": 4,
          "text": "Active peptic ulcer"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Tenecteplase </strong>is used for fibrinolytic therapy. An<strong> active peptic ulcer</strong> is a <strong>relative contraindication</strong> to fibrinolytic therapy. Other options are absolute contraindications.</p>\n<p>&nbsp;<strong>Absolute Contraindications </strong>to fibrinolytic therapy:</p>\n<ul>\n<li><strong>Known malignant intracranial neoplasm</strong></li>\n<li>Prior intracranial hemorrhage</li>\n<li><strong>Ischemic stroke</strong> within the <strong>last 3 months</strong></li>\n<li>Known structural cerebral vascular lesion</li>\n<li><strong>Suspicion</strong> of <strong>aortic dissection</strong></li>\n<li>Active bleeding or bleeding diathesis (excluding menstrual bleeding)</li>\n<li>Significant closed head trauma or facial trauma within 3 months</li>\n</ul>\n<p><strong>Relative Contraindications&nbsp;</strong>to fibrinolytic therapy:</p>\n<ul>\n<li>Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;110 mmHg)</li>\n<li><strong>Active peptic ulcer</strong></li>\n<li>Noncompressible vascular punctures</li>\n<li>Traumatic or prolonged CPR or major surgery within 3 weeks</li>\n<li>Recent (within 2&ndash;4 weeks) internal bleeding</li>\n<li>For streptokinase: prior exposure (more than 5 days ago) or prior allergic reaction to streptokinase</li>\n<li>Pregnancy</li>\n<li>Current use of warfarin and INR &gt;1.7</li>\n</ul><hr><h3>Related Pearl: Plasminogen activators (classification of fibrinolytics)</h3><p><strong>Fibrin non-specific</strong> plasminogen activators</p>\n<ul>\n<li>Streptokinase - least fibrin specific and has the lowest incidence of intracranial hemorrhage</li>\n<li>Anistreplase</li>\n<li>Urokinase</li>\n</ul>\n<p><strong>Fibrin specific</strong> plasminogen activators</p>\n<ul>\n<li>Alteplase - has the shortest half-life</li>\n<li>Tenecteplase - most fibrin specific and given as a single bolus dose</li>\n<li>Reteplase</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7259",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following antifungal drugs is matched correctly with its mechanism of action based on the image given below?",
      "choices": [
        {
          "id": 1,
          "text": "A - Flucytosine"
        },
        {
          "id": 2,
          "text": "B - Griseofulvin"
        },
        {
          "id": 3,
          "text": "C - Amphotericin"
        },
        {
          "id": 4,
          "text": "D - Terbinafine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Amphotericin B </strong>is an<strong> amphipathic molecule</strong> and incorporates itself in the cell membrane by actively binding to <strong>ergosterol</strong> (as shown in the image by '<strong>C</strong>'). This results in the formation of <strong>amphotericin-induced pores</strong> which cause leakage of the intracellular contents ultimately resulting in cell death.</p>\n<p>It is a <strong>broad-spectrum antifungal</strong> that can be used against<em> Candida albicans, Cryptococcus neoformans, Blastomyces dermatitidis, Histoplasma capsulatum, Sporothrix schenckii,&nbsp;</em><em>Coccidioides immitis, Aspergillus.</em></p>\n<p><strong>Amphotericin B</strong> also has <strong>antiprotozoal</strong> action along with antifungal properties and is effective against <strong><em>Leishmania</em></strong><em>.</em></p>\n<p><strong>Adverse effects</strong> of amphotericin B include:</p>\n<ul>\n<li>Infusion-related fever and chills</li>\n<li><strong>Azotemia/nephrotoxicity</strong>- all lipid formulations of amphotericin B are less nephrotoxic than conventional amphotericin B</li>\n<li><strong>Renal tubular acidosis&nbsp;</strong></li>\n<li>Renal wasting of potassium and magnesium</li>\n<li>Hypochromic normocytic anemia- due to decreased erythropoietin production from the kidney.</li>\n</ul><hr><h3>Related Pearl: Mechanism of action of Antifungal drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e48d5ad74a9b48c6baa33c90914e13cbx1280x2560.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/93bd46631d294c00acd68ec7cf7bcbfb.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0522",
      "difficulty": "easy"
    },
    {
      "text": "A 55-year-old female patient came to the hospital with a history of headaches, seizures, memory loss, and mood changes.  The given image is obtained by doing an MRI scan. Which of the following drugs is useful in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Streptozocin"
        },
        {
          "id": 2,
          "text": "Temozolomide"
        },
        {
          "id": 3,
          "text": "Ifosfamide"
        },
        {
          "id": 4,
          "text": "Chlorambucil"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical vignette and the MRI scan finding are suggestive of<strong> glioblastoma. Temozolomide</strong> is used as a <strong>first-line agent</strong> for the management of <strong>glioblastoma.</strong> It is used for newly diagnosed cases along with radiotherapy and also used for maintenance therapy.</p>\n<p>Temozolomide belongs to the <strong>triazene group</strong> of <strong>alkylating agents</strong> and is administered orally. The <strong>oral bioavailability</strong> of temozolomide is nearly <strong>100%</strong>. It forms a methylating metabolite and kills cells in all phases of the cell cycle.</p>\n<p>Glioblastoma is the most malignant astrocytic tumor - WHO grade IV. It spreads along the white matter tracts and crosses the midline via the corpus callosum, giving rise to the so-called <strong>butterfly glioma. </strong></p>\n<p>Other options:</p>\n<p>Option A- <strong>Streptozocin</strong> belongs to the nitrosourea group of alkylating agents and has a high affinity of islets of Langerhans. It is used in the treatment of <strong>pancreatic islet cell carcinoma</strong> and carcinoid tumors.</p>\n<p>Option C- <strong>Ifosfamide</strong> belongs to the nitrogen mustard group of alkylating agents and an analog of cyclophosphamide. Ifosfamide is used in germ cell tumors of testes and sarcomas. It has maximum <strong>neurotoxicity</strong> which can be treated with <strong>methylene blue</strong>. It has a urothelial damaging capacity like cyclophosphamide which can be treated with MESNA (sodium-2-mercaptoethanol sulfonate).</p>\n<p>Option D- <strong>Chlorambucil</strong> belongs to the nitrogen mustard group of alkylating agents and is an orally administered drug. It is almost exclusively used in the treatment of <strong>chronic lymphocytic leukemia.</strong></p><hr><h3>Related Pearl: Classification of antineoplastic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fd047e306bdc4310be749978ffaf0c5dx1280x1780.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>&nbsp; &nbsp;Non-cell-cycle specific drugs</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Alkylating agents</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Nitrogen mustards</p>\n<ul>\n<li>Cyclophosphamide</li>\n<li>Ifosfamide</li>\n<li>Mechlorethamine</li>\n<li>Melphalan</li>\n<li>Chlorambucil</li>\n<li>Bendamustine</li>\n</ul>\n<p>Nitrosoureas</p>\n<ul>\n<li>Carmustine</li>\n<li>Lomustine</li>\n<li>Semustine</li>\n<li>Streptozocin</li>\n</ul>\n<p>Triazines (methylating agents)</p>\n<ul>\n<li>Procarbazine</li>\n<li>Dacarbazine</li>\n<li>Temozolomide</li>\n</ul>\n<p>Ethyleneimines</p>\n<ul>\n<li>Altretamine</li>\n<li>Thio-TEPA</li>\n</ul>\n<p>Alkyl sulfonates</p>\n<ul>\n<li>Busulfan</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Platinum compounds</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Cisplatin</li>\n<li>Carboplatin</li>\n<li>Oxaliplatin&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Anti-tumor antibiotics</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Anthracyclines</p>\n<ul>\n<li>Doxorubicin (adriamycin)</li>\n<li>Daunorubicin (rubidomycin)</li>\n<li>Epirubicin</li>\n<li>Valrubicin</li>\n<li>Mitoxantrone</li>\n</ul>\n<p>Others</p>\n<ul>\n<li>Actinomycin-D (Dactinomycin)</li>\n<li>Mitomycin-C</li>\n<li>Bleomycin (also a G2-M phase inhibitor)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong> Cell-cycle specific drugs</strong></td>\n</tr>\n<tr>\n<td><strong>S-phase inhibitors</strong></td>\n</tr>\n<tr>\n<td><strong>Antimetabolites</strong></td>\n</tr>\n<tr>\n<td>Antifolate\n<ul>\n<li>Methotrexate</li>\n<li>Pemetrexed</li>\n<li>Pralatrexate</li>\n<li>Raltitrexed</li>\n</ul>\nPurine analogues\n<ul>\n<li>6-Mercaptopurine</li>\n<li>6-Thioguanine</li>\n<li>Fludarabine</li>\n<li>Cladribine</li>\n<li>Pentostatin</li>\n</ul>\nPyrimidine analogues\n<ul>\n<li>5-Fluorouracil</li>\n<li>Capecitabine</li>\n<li>Gemcitabine</li>\n<li>Cytarabine</li>\n</ul>\n&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Topoisomerase inhibitors</strong></td>\n</tr>\n<tr>\n<td>Topoisomerase-1 inhibitors (ca)\n<ul>\n<li>Irinotecan</li>\n<li>Topotecan</li>\n</ul>\nTopoisomerase-2 inhibitors\n<ul>\n<li>Etoposide</li>\n<li>Teniposide</li>\n</ul>\n&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Histone deacetylase inhibitors</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Vorinostat</li>\n<li>Belinostat</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Others </strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>&nbsp;Hydroxyurea</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td><strong>M-phase inhibitors (antimitotics or microtubule damaging agents)</strong></td>\n</tr>\n<tr>\n<td><strong>Vinca alkaloids</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Vincristine(Oncovin)</li>\n<li>Vinblastine</li>\n<li>Vinorelbine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Taxanes</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Paclitaxel</li>\n<li>Docetaxel</li>\n<li>Cabazitaxel</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Others</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Epothilones</li>\n<li>Eribulin</li>\n<li>Estramustine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>G1-S phase inhibitor</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Epipodophyllotoxin</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/3e9c4d7e004740ebade58c2cdf79f4e3.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1848",
      "difficulty": "medium"
    },
    {
      "text": "Romiplostim is a",
      "choices": [
        {
          "id": 1,
          "text": "Recombinant human erythropoietin"
        },
        {
          "id": 2,
          "text": "Recombinant human granulocyte colony-stimulating factor"
        },
        {
          "id": 3,
          "text": "Recombinant human IL-11"
        },
        {
          "id": 4,
          "text": "Thrombopoietin receptor agonist"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Romiplostim </strong>is a<strong>&nbsp;thrombopoietin receptor agonist</strong>. It is used in the management of immune thrombocytopenia (ITP).&nbsp;<strong>Eltrombopag</strong> is also a&nbsp;thrombopoietin receptor agonist. It is used in the treatment of ITP and severe aplastic anemia.</p>\n<p>Other options:</p>\n<p class=\"p1\">Option A- <strong>Epoetin alfa</strong> and <strong>darbepoetin alfa</strong> are&nbsp;<strong>recombinant human erythropoietin</strong>. They can be used in the treatment of <strong>anemias</strong> associated with surgery, AIDS, cancer chemotherapy, prematurity, and certain chronic inflammatory conditions.&nbsp;</p>\n<p class=\"p1\">Option B- <strong>Filgrastim</strong> is a <strong>recombinant&nbsp;granulocyte colony-stimulating factor.&nbsp;</strong>It increases neutrophil production. It is used in the treatment of <strong>neutropenia</strong>. Important adverse reactions include bone pain, local skin reaction, and cutaneous necrotizing vasculitis.</p>\n<p class=\"p1\">Option C- <strong>Oprelvekin</strong> is a recombinant <strong>human IL-11</strong>. It increases thrombopoiesis. It is used in the treatment of <strong>thrombocytopenia</strong> due to non-myeloid malignancies. Important adverse effects are&nbsp;fluid retention, tachycardia, palpitation, edema, and shortness of breath.</p>\n<p class=\"p1\"><strong>Sargramostim</strong> is a recombinant granulocyte-macrophage colony-stimulating factor. It stimulates <strong>myelopoiesis</strong>. Important adverse effects are&nbsp;bone pain, malaise, flu-like symptoms, diarrhea, dyspnea, and rash.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9166",
      "difficulty": "medium"
    },
    {
      "text": "All of the following statements are true regarding digoxin, except:",
      "choices": [
        {
          "id": 1,
          "text": "It is one of the cardiac glycosides"
        },
        {
          "id": 2,
          "text": "It inhibits sodium-potassium ATPase pump"
        },
        {
          "id": 3,
          "text": "It can cause premature ventricular depolarisations"
        },
        {
          "id": 4,
          "text": "Hypermagnesemia increases the risk of digitalis induced arrhythmia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Hypomagnesemia</strong> increases the risk of digitalis-induced arrhythmia.&nbsp;</p>\n<p>Digoxin is one of the cardiac glycosides which is derived from the&nbsp;<strong>digitalis plant</strong> and used clinically.</p>\n<p>It inhibits <strong>Na<sup>+</sup>/K<sup>+&nbsp;</sup>ATPase</strong>, a membrane-bound transporter to increase intracellular sodium. As a result, there is less expulsion of calcium from the cell by sodium-calcium exchanger (<strong>NCX).&nbsp;</strong>Increased calcium inside the myocyte leads to<strong>&nbsp;an increase </strong>in cardiac contractility.</p>\n<p>Digoxin is 65&ndash;80% absorbed after oral administration. An almost two-third of the metabolite is excreted unchanged by <strong>kidney</strong> with half-life of 36-40 hours.</p>\n<p>The most common cardiac manifestations of digitalis toxicity include atrioventricular junctional rhythm, <strong>premature ventricular depolarizations, </strong>ventricular bigeminy,<strong> ventricular tachycardia,</strong> and<strong> second-degree AV blockade</strong>. After cardiovascular system, nausea, vomiting, diarrhea i.e., <strong>GIT effects </strong>are more pronounced.&nbsp;<strong>Altered color perception</strong> can also be seen in case of digoxin toxicity.</p>\n<p>Factors that increase the risk of digoxin toxicity are:</p>\n<ul>\n<li><strong>Hypercalcemia</strong></li>\n<li><strong>Hypomagnesemia</strong></li>\n<li><strong>Hypokalemia</strong>- It increases the binding of the digoxin to the&nbsp;Na<span class=\"s1\">+</span>/K<span class=\"s1\">+&nbsp;</span>ATPase pump.&nbsp;</li>\n<li>Drugs causing hypokalemia- Diuretics, amphotericin B, corticosteroids</li>\n<li>Drugs that decrease digoxin elimination (inhibitors of P-glycoprotein)-&nbsp;Amiodarone, quinidine, verapamil, diltiazem, cyclosporine, itraconazole, propafenone, and flecainide</li>\n<li>Renal failure</li>\n<li>Hypothyroidism</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6780",
      "difficulty": "medium"
    }
  ]
}